  
 
 
 
IONIS  PHARMACEUTICALS, INC.  
 
 
ISIS  420915-CS2 
 
A Phase 2/3 Randomized, Double- Blind, Placebo -Controlled Study 
to Assess the Efficacy and Safety of ISIS  420915 in Patients with 
Familial Amyloid Polyneuropathy  
 
Protocol Amendment 9  – 13 May 2016 
 
EudraCT No: 2012-001831-30 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

I SI S  4 2 0 9 1 5 -C S 2  C O N FI D E N TI A L  A me n d me nt 9  
Pr ot oc ol   1 3 Ma y 2 0 1 6  
 
2 I SI S  4 2 0 9 1 5 - C S 2 
 
A P h ase 2/ 3 R a n d o mi ze d, D o u bl e -Bli n d, Pl ace b o -C o ntr olle d St u d y t o 
Assess t he Effic ac y a n d S afet y of I SI S  4 2 0 9 1 5  i n P ati e nts wit h F a mili al 
A m yl oi d P ol y ne u r o p at h y  
 
Pr ot oc ol A me n d me nt 9  – 1 3 M a y  2 0 1 6  
 
Pr ot oc ol  Hist or y: 
Ori gi nal Pr ot oc ol:   2 1 Se pte m ber 2 0 1 2 
A me n d me nt 1: 1 4 Dece m b er  2 0 1 2 
A me n d me nt 2:   5 Marc h 2 0 1 3 
A me n d me nt 3:  9 Dece m b er 2 0 1 3  
A me n d me nt 4:   1 2 J u ne 2 0 1 4 
A me n d me nt 5:   9 J a n uar y 2 0 1 5 
A me n d me nt 6:   2 9 A pril 2 0 1 5 
A me n d me nt 7:   1 6 N o ve m ber 2 0 1 5 
A me n d me nt 8:   7 Marc h 2 0 1 6 
 
S p o ns or:  
I o nis P har m ace uticals, I n c.  
2 8 5 5 Gazelle C o urt 
Carls ba d, C A  9 2 0 1 0 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ P P D 
, M. D. , M. B. A. 
,   P P D 
P P D P P D 
I SI S  4 2 0 9 1 5 -C S 2  C O N FI D E N TI A L  A me n d me nt 9  
Pr ot oc ol   1 3 Ma y 2 0 1 6  
 
3   
I SI S 4 2 0 9 1 5  
Io nis  Pr ot oc ol N u m ber I SI S  4 2 0 9 1 5- C S 2 
Pr ot oc ol A me n d me nt 9  
E u dr a C T N o: 2 0 1 2- 0 0 1 8 3 1- 3 0  
 
Cli nic al P h ase:   2/ 3 
A P h ase 2/ 3 R a n d o mize d, D o u ble -Bli n d, Pl ace b o -C o ntr olle d St u d y 
t o Assess t he Effic ac y a n d S afet y of I SI S 4 2 0 9 1 5  i n P atie nts wit h 
F a mili al A m yl oi d P ol y ne ur o p at h y  
Trial S p o ns or:  Io nis  P har mace uticals, I nc.  
2 8 5 5 Gazelle C o urt  
Carls ba d, C A 9 2 0 1 0  
P h o ne :  
Fa x :  
Ke y S p o ns or C o ntact:  , P h. D.  
, Cli nical De vel o p me nt  
Io nis  P har mace uticals, I nc.  
2 8 5 5 Gazelle C o urt  
Carls ba d, C A 9 2 0 1 0  
P h o ne :  
Date:  1 3 Ma y  2 0 1 6  
  
C o nfi de nti alit y St ate me nt  P P D 
T his d oc u me nt c o ntai ns c o nfi de ntial i nf or mati o n of I o nis P har mace uticals, I nc.  t hat m ust n ot be 
discl ose d t o a n y o ne ot her t ha n t he reci pie nt st u d y staff a n d me m bers of t he i n de pe n de nt et hics 
c o m mittee, i nstit uti o nal re vie w b oar d, or a ut h orize d r e g ulat or y a ge ncies.   T his i nf or mati o n 
ca n n ot be use d f or a n y p ur p ose ot her t ha n t he e val uati o n or c o n d uct of t he cli nical i n vesti gati o n 
wit h o ut t he pri or writte n c o nse nt of I o nis P har mace uticals, I nc.  P P D 
P P D 
P P D 
P P D 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 420915- CS2 
Protocol Title:  A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to 
Assess the Efficacy and Safety of ISIS  420915 in Patients with Familial 
Amyloid Polyneuropathy 
Amendment:  Amendment 9  
Date:    13 May 2016 
 
I hereby acknowledge that I have read and understand the attached clinical protocol , entitled “ A 
Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS  420915 in Patients with Familial Amyloid Polyneuropathy ”, dated 13 May 2016, 
and agree t o conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be us ed for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Isis Pharmaceuticals, Inc.  
 
 
  
   
Investigator’s Signature 
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................14  
STUDY DESIGN AND TREATMENT SCHEMA ...................................................................19  
STUDY GLOSSARY  ...................................................................................................................20  
1. OBJECTIVES  .......................................................................................................................22  
1.1 Primary Ob jectives  .........................................................................................................22  
1.2 Secondary Objectives  .....................................................................................................22  
1.3 Tertiary Objectives  .........................................................................................................22  
1.4 Exploratory Objectives  ..................................................................................................22  
2. BACKGROUND AND RATIONALE  ................................................................................23  
2.1 Overview of Disease  ......................................................................................................23  
2.1.1  Transthyretin Amyloidosis .........................................................................................23  
2.1.2  Current Therapies  .......................................................................................................24  
2.2 Therapeutic Rationale  ....................................................................................................25  
2.3 ISIS 420915 ...................................................................................................................26  
2.3.1  Mechan ism of Action  .................................................................................................26  
2.3.2  Chemistry  ...................................................................................................................26  
2.3.3  Preclinical Experience  ................................................................................................27  
2.3.4  Clinical Experience  ....................................................................................................28  
2.4 Rationale for Dose and Schedule of Administration .....................................................28  
3. EXPERIMENTAL PLAN  ...................................................................................................29  
3.1 Study Design ..................................................................................................................29  
3.2 Number o f Study Centers ...............................................................................................30  
3.3 Number of Patients  ........................................................................................................30  
3.4 Overall Study Duration and Follow- up ..........................................................................30  
3.4.1  Screening and Baseline Assessment  ...........................................................................30  
3.4.2  Treatment and EOT Efficacy Assessment  ..................................................................31  
3.4.3  Post-Treatment  ...........................................................................................................31  
3.5 End of Study ..................................................................................................................31  
3.6 Data Safety and Monitoring Board ................................................................................31  
4. PATIENT ENROLLMENT  ................................................................................................31  
4.1 Screening ........................................................................................................................31  
4.2 Randomization ...............................................................................................................32  
4.3 Replacement of Patients  .................................................................................................32  
4.4 Unblinding of Treatment Assignment ...........................................................................32  
5. PATIENT ELIGIBILITY  ....................................................................................................33  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
6  5.1 Inclusion Criteria  ...........................................................................................................33  
5.2 Exclusion Criteria  ..........................................................................................................33  
5.3 Additional Eligibility Criteria for Patients Participating in the ECHO Subgroup  .........35  
6. STUDY PROCEDURES  ......................................................................................................35  
6.1 Study Schedule...............................................................................................................35  
6.1.1  Screening and Baseline Assessment Period  ...............................................................35  
6.1.2  Treatment Period  ........................................................................................................36  
6.1.3  EOT Efficacy Assessment Period  ..............................................................................38  
6.1.4  Post-Treatment Period  ................................................................................................38  
6.2 Additional Study Assessments .......................................................................................38  
6.2.1  Laboratory Assessments .............................................................................................38  
6.2.2  Congestive Heart Failure ............................................................................................38  
6.2.3  Arrhythmias  ................................................................................................................39  
6.2.4  Myocardial Ischemia ..................................................................................................39  
6.2.5  Event- Specific Supplemental CRF Pages  ..................................................................39  
6.3 Restriction on the Lifestyle of Patients  ..........................................................................39  
6.3.1  Contraception Requirements ......................................................................................39  
6.3.2  Other Requirements ....................................................................................................41  
7. STUDY DRUG  ......................................................................................................................41  
7.1 ISIS 420915 or Placebo .................................................................................................41  
7.2 Packaging and Labeling .................................................................................................41  
7.3 Study Drug Accountability ............................................................................................41  
8. TREATMENT OF PATIENTS  ...........................................................................................41  
8.1 Study Drug Administration ............................................................................................41  
8.2 Other Protocol-Required Drugs .....................................................................................42  
8.3 Other Protocol-Required Treatment Procedures ............................................................42  
8.4 Treatment Precautions  ...................................................................................................42  
8.5 Safety Monitoring Rules ................................................................................................42  
8.5.1  Safety Monitoring Rules for Liver Chemistry Tests ..................................................43  
8.5.2  Safety Monitoring Rules for Renal Function .............................................................43  
8.5.3  Safety Monitoring Rules for Ocular Effects ...............................................................44  
8.5.4  Safety Monitoring Rules for Platelet Count Results ..................................................45  
8.6 Stopping Rules ...............................................................................................................45  
8.6.1  Stopping Rules for Liver Chemistry Elevations .........................................................45  
8.6.2  Stopping Rules for Renal Function Test Results ........................................................46  
8.6.3  Stopping Rule for Platelet Count Results ...................................................................46  
8.6.4  Stopping Rule for Ocular Effects ...............................................................................47  
8.6.5  Stopping Rule for QTc Prolongation ..........................................................................47  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
7  8.7 Adjustment of Dose and/or Treatment Schedule ...........................................................48  
8.8 Discontinuation of Study Treatment ..............................................................................48  
8.9 Withdrawal of Patients from the Study  ..........................................................................49  
8.10  Concomitant Therapy and Procedures ...........................................................................49  
8.10.1  Concomitant Therapy .................................................................................................49  
8.10.2  Concomitant Procedures .............................................................................................50  
8.11  Treatment Compliance  ...................................................................................................50  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ............................50  
9.1 Sponsor Review of Safety Information..........................................................................50  
9.2 Regulatory Requirements  ...............................................................................................50  
9.3 Definitions ......................................................................................................................51  
9.3.1  Adverse Event ............................................................................................................51  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..................................................51  
9.3.3  Serious Adverse Event (SAE)  ....................................................................................51  
9.4 Monitoring and Recording Adverse Events  ...................................................................52  
9.4.1  Serious Adverse Events  ..............................................................................................52  
9.4.2  Non-Serious Adverse Events ......................................................................................52  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ........................................53  
9.4.3.1  Relationship to the Study Drug  ......................................................................... 53  
9.4.3.2  Severity  ............................................................................................................. 53  
9.4.3.3  Action Taken with Study Drug ......................................................................... 53  
9.4.3.4  Treatment Given for Adverse Event  ................................................................. 54  
9.4.3.5  Outcome of the Adverse Event ......................................................................... 54  
9.5 Procedures for Handling Special Situations ..................................................................54  
9.5.1  Abnormalities of Laboratory Tests .............................................................................54  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments ................55  
9.5.3  Dosing Errors  .............................................................................................................55  
9.5.4  Contraception and Pregnancy .....................................................................................55  
10. STATISTICAL CONSIDERATIONS  ................................................................................56  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................56  
10.1.1  Primary Endpoints ......................................................................................................56  
10.1.2  Secondary Endpoints ..................................................................................................56  
10.1.2.1  Secondary Efficacy Endpoints ...................................................................... 56  
10.1.2.2  Pharmacodynamic Endpoint ......................................................................... 56  
10.1.2.3  Safety Endpoints ........................................................................................... 57  
10.1.2.4  Pharmacokinetic Endpoints .......................................................................... 57  
10.1.3  Tertiary Endpoint .......................................................................................................57  
10.1.4  Exploratory Endpoints  ................................................................................................58  
10.2  Sample Size Considerations ...........................................................................................58  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
8  10.3  Populations .....................................................................................................................58  
10.4  Interim Analysis  .............................................................................................................59  
10.5  Planned Methods of Analysis ........................................................................................59  
10.5.1  Demographic and Baseline Characteristics  ................................................................59  
10.5.2  Safety Analysis  ...........................................................................................................59  
10.5.3  Efficacy Analysis  .......................................................................................................60  
10.5.4  Pharmacokinetic Analysis ..........................................................................................62  
10.5.5  Pharmacodynamic Analysis  .......................................................................................62  
10.5.6  Exploratory Analysis  ..................................................................................................62  
11. INVESTIGATOR'S REGULATORY OBLIGATIONS  ..................................................62  
11.1  Informed Consent ...........................................................................................................62  
11.2  Ethical Conduct of the Study .........................................................................................63  
11.3  Independent Ethics Committee/Institutional Review Board ..........................................63  
11.4  Patient Confidentiality  ...................................................................................................63  
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  ......................................................64  
12.1  Protocol Amendments ....................................................................................................64  
12.2  Study Termination .........................................................................................................64  
12.3  Study Documentation and Storage.................................................................................64  
12.4  Study Monitoring ...........................................................................................................65  
12.5  Language ........................................................................................................................66  
12.6  Compensat ion for Injury ................................................................................................66  
13. REFERENCES  .....................................................................................................................67  
14. APPENDICES  ......................................................................................................................70  
Appendix A  Schedule of Procedures ......................................................................................71  
Appendix B  List of Laboratory Analytes  ...............................................................................78  
Appendix C  PK Sampling Schedule ......................................................................................80  
 
TABLE OF TABLES  
Page 
Table 1  Study Drug Characteristics  ................................................................................... 41  
 
TABLE OF FIGURES  
Page 
Figure 1  Design of Chimeric 2ʹ -MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer).  The sequence of ISIS  420915 is shown ................................... 27  
  
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
9  PROTOCOL AMENDMENT 
 
Protocol Number:   ISIS 420915-CS2 
Protocol Title:  A Phase 2/3 Randomized, Double- Blind, Placebo-Controlled Study 
to Assess the Efficacy and Safety of ISIS 420915 in Patients with 
Familial Amyloid Polyneuropathy 
Amendment Number:  9 
Amendment Date:  13 May 2016 
 
The main purpose of this amendment is to increa se the frequency of platelet monitoring from 
every 2-3 weeks, to every week throughout the treatment period and for a minimum of 6 weeks 
after the last dose of Study Drug.  This change wa s made in response to a recently reported case 
of severe thrombocytopenia in this study and in consultation with th e independent DSMB.  
Previous to this recent case, two other pa tients in this study ha ve developed severe 
thrombocytopenia, one of whom experienced a fatal intracranial bleed. 
Minor changes (not included in the list of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design. 
The following table provides a summary list of major changes to the protocol: 
Protocol Section Description of Change Rationale 
3.4.3 
Post-Treatment Was: 
The post-treatment evaluat ion period is 6 months 
and consists of 3 Study Center visits on Weeks 71, 
77 and 91.  The final study visit is Week 91. 
 
Is: 
The post-treatment evaluat ion period is 6 months 
and consists of Study Center visits and additional 
safety testing.   The final study visit is Week 91. Language with regard to the visit schedule and laboratory safety 
testing has been updated to 
reflect the new schedule of 
procedures. 
6.1.2 Treatment Period Was: 
Patients will report to the Study Center for Study 
Drug administration, evaluations, and tests 24 times during Weeks 2-65 (see Schedule of Procedures in 
Appendix A). 
 Is: 
Patients will report to the Study Center for Study 
Drug administration, evaluations, and tests regularly 
throughout the treatment period and will have 
weekly safety testing according to the  schedule of 
procedures in Appendix A. Language with regard to the visit schedule and laboratory safety testing has been updated to 
reflect the new schedule of 
procedures. 
  
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
10  Protocol Section Description of Change Rationale 
6.1.2 
Treatment Period Continued  Was: 
To help reduce patient travel burden, 13 clinic visits may be done as non-clinic visits during the treatment 
period.  For non-clinic visits, collection of vital signs and labs (as indicated in the Schedule of 
Procedures) can be performed by the Sponsor’s 
home healthcare service or by a local laboratory with 
prior Sponsor approval.  The selected visits are at 
Weeks 10, 15, 20, 23, 26, 32,  38, 41, 44, 50, 56, 59, 
and 62.  At Weeks 23, 41 and 59, adverse events should be collected by the site personal through a 
phone contact with the patient. 
 Is: 
To help reduce patient travel burden, some clinic 
visits and weekly safety testing between  visits 
may be done as non-clinic visits.  For non-clinic 
visits, collection of vital signs and labs (as indicated 
in the Schedule of Procedures) can be performed by 
the Sponsor’s home healthcare service or by a local 
laboratory with prior Sponsor approval. Language with regard to the visit 
schedule and laboratory safety 
testing has been updated to 
reflect the new schedule of 
procedures. 
6.1.4 
Post-Treatment Period Was: 
After completion of the EOT efficacy assessment, 
patients will enter the 6-month post-treatment 
evaluation period.  This per iod consists of 8 Study 
Center visits on Weeks 67, 69, 71, 74, 77, 80, 83, 
and 91 as outlined in the schedule of procedures 
(Appendix A).  Weeks 67, 69, 71, 74, 80 and 83 may 
be done as a non-clinic visit where collection of vital 
signs and labs may be collected by the Sponsor’s 
home healthcare service or by a local laboratory with 
prior Sponsor approval.  At Week 71, adverse events 
should be collected by the site personal through a 
phone contact with the patient. 
Alternatively, after comple tion of the EOT efficacy 
assessment, eligible patien ts may elect to receive 
ISIS 420915 in an OLE study, pending study 
approval by the IRB/IEC and the appropriate 
regulatory authority.  In this case, patients will not 
participate in the post-treatment evaluation period. 
 Is: 
After completion of the EOT efficacy assessment, 
patients will enter the 6-month post-treatment 
evaluation period and will report to the study 
center and have weekly platelet monitoring for a 
minimum of 6 weeks after the last dose of Study 
Drug which may be collected by the clinic, 
Sponsor’s home healthcare service or by a local 
laboratory  as outlined in the sc hedule of procedures 
(Appendix A).  At Week 71, adverse events should 
be collected by the site personal through a phone 
contact with the patient if a clinic visit was not 
conducted. Language with regard to the visit 
schedule and laboratory safety testing has been updated to 
reflect the new schedule of 
procedures. 
  
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
11  Protocol Section Description of Change Rationale 
6.1.4 
Post-Treatment Period Continued Is: Continued 
Alternatively, after comple tion of the EOT efficacy 
assessment, eligible patien ts may elect to receive 
ISIS 420915 in an OLE study (ISIS 420915-CS3) , 
pending study approval by the IRB/IEC and the appropriate regulatory authority.  In this case, 
patients will not participat e in the post-treatment 
evaluation period but weekly platelet monitoring 
should continue between the last dose of Study 
Drug in CS2 and the first dose of Study Drug in 
CS3.  If this period extends beyond 6 weeks, the 
frequency will be determined by the Study 
Medical Monitor.  Language with regard to the visit 
schedule and laboratory safety 
testing has been updated to 
reflect the new schedule of 
procedures. 
6.2.1 Laboratory 
Assessments  Deleted: 
Each time a hematology lab is collected a duplicate 
sample (e.g., local lab) should also be collected in 
parallel.  If both the central and local platelet value is uninterpretable (e.g., due to clumping, hemolysis or 
quantity not sufficient) a repeat hematology lab must 
be collected as soon as possible (within 7 days after 
the unreportable value). Because platelet counts will be 
monitored more frequently, the 
requirement to collect a local lab 
sample at the same time as the 
samples for the central lab has 
been removed. 
8.5.4 
Safety Monitoring 
Rules for Platelet 
Count Results Was: 
If a patient’s platelet count falls by 30% or greater 
from baseline or the absol ute platelet count is 
100,000/mm3 or less, then the patient’s platelet 
counts should be monitored more frequently.  The 
frequency of monitoring and additional lab tests will 
be determined by the Investigator in consultation 
with the Study Medical Monitor.  Additional details on 
monitoring platelets are described in the Safety 
Management Plan. 
 
Is: 
Platelets will be monitored weekly throughout 
the treatment period and for a minimum of 
6 weeks after the last dose of Study Drug (this 
includes early termination patients as well as 
patients that complete the full 65-week treatment 
period).  For patients participating in the Post-
Treatment Evaluation Period, frequency of 
testing after the Week 71 visit will be determined 
by the Investigator in consultation with the Study 
Medical Monitor.  For patients participating in the 
ISIS 420915-CS3 study, weekly monitoring 
should continue between the last dose of Study 
Drug in CS2 and first dose of Study Drug in CS3.  
If this period extends beyond 6 weeks, the 
frequency of monitoring will be determined by 
the Study Medical Monitor. 
All platelet count results must be promptly 
reviewed by the Investigator to ensure that the 
count has not met the stopping rule.  The monitoring rule has been 
updated to reflect the weekly 
platelet monitoring and to 
indicate that dosing must be 
held if there is more than 14 days between interpretable 
platelet values. 
  
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
12  Protocol Section Description of Change Rationale 
8.5.4 
Safety Monitoring 
Rules for Platelet 
Count Results 
Continued Is: Continued 
If, for any reason, there is more than 14 days 
between platelet values (e.g., lab report of an 
unreadable sample due to clumping, hemolysis, or quantity not sufficient, or a missed lab 
assessment), the Investigator will contact the 
patient to hold dosing until a new platelet value 
is obtained and reviewed. 
If a patient’s platelet counts fall below 
100,000/mm3, additional lab tests may be 
requested as determined by the Investigator in consultation with the Study Medical Monitor.  The monitoring rule has been 
updated to reflect the weekly 
platelet monitoring and to 
indicate that dosing must be 
held if there is more than 
14 days between interpretable 
platelet values. 
8.6.3 
Stopping Rule for Platelet Count Results Was: 
In the event of a confirmed platelet count less than 
75,000/mm3, and in the absence of major bleeding or 
clinically-relevant non-major bleeding, further dosing 
of a patient with Study Drug (ISIS 420915 or 
placebo) must be held until the platelet count returns 
to at least 100,000/mm3.  In addition, platelet counts 
should be monitored weekly (or more frequently as determined by the Study Medical Monitor) until they 
return above 75,000/mm3. 
 
Is: 
In the event of a confirmed platelet count less than 
75,000/mm3, and in the absence of major bleeding or 
clinically-relevant non-major bleeding, further dosing of a patient with Study Drug (ISIS 420915 or 
placebo) must be held until the platelet count returns 
to at least 100,000/mm3.  Weekly platelet 
monitoring should continue during this period.  
In addition, the Investigator should give 
consideration to collecting duplicate platelet 
samples for study in a local  lab in parallel to the 
central lab if it would provide quicker access to the patients platelet count.  If the platelet count 
was confirmed to be < 50,000/mm3, then 
monitoring should be increased to daily until two successive values show improvement.  The 
Investigator must notify the Study Medical 
Monitor within 24 hours of any local lab platelet 
results that show a level < 50,000/mm3. Platelet stopping rule has been 
updated to indicate daily platelet monitoring is required if the 
platelet value is < 50,000/mm3 
and that the Investigator is required to inform the Study 
Medical Monitor within 24 hours 
if a local platelet value is  
< 50,000/mm3. 
Appendix A Schedule of Procedures  Deleted: 
To accommodate scheduling, visit windows may be used, however hematology collections must be 
collected no more than 2-3 weeks apart. 
+ Each time a hematology lab is collected a 
duplicate sample (e.g., local lab) should also be 
collected in parallel.  If both the central and local 
platelet value is uninterpretable (e.g., due to 
clumping, hemolysis or quantity not sufficient) a 
repeat hematology lab must  be collected as soon as 
possible (within 7 days after the unreportable value). The schedule of procedures was updated to reflect the weekly platelet monitoring and removal 
of duplicate platelet collection. 
  
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
13  Protocol Section Description of Change Rationale 
Appendix A Schedule 
of Procedures 
Continued Added: 
Weekly platelet monitoring was added throughout 
the treatment period and up to Week 71 in the post-
treatment evaluation period. 
 Footnote to weekly platelet monitoring added: 
Weekly platelet monitoring is required throughout the 
treatment period and for a minimum of 6 weeks after 
the last dose of Study Drug (this includes early 
termination patients as well as  patients that complete 
the full 65-week treatment period).  For patients participating in the Post-Treatment Evaluation 
Period, frequency of testing after the Week 71 visit 
will be determined by the Study Medical Monitor in 
consultation with the Investigator.  For patients 
participating in the ISIS 420915-CS3 study, weekly 
monitoring should continue between the last dose of Study Drug in CS2 and first dose of Study Drug in 
CS3.  If this period extends beyond 6 weeks, the 
frequency will be determined by the Study Medical 
Monitor. 
The following visits to collect platelet values are 
required in addition to the visits shown in the table. 
These visits do not have specified windows to allow 
flexibility of scheduling but  with the intent that 
platelets are assessed each calendar week.  Visits 
may be completed in clinic, by home healthcare 
service, or by a local laboratory: 
Week 2, 4, 6, 7, 9, 11, 12,  14, 16, 17, 19, 21, 22, 24, 
25, 27, 28, 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 
46, 48, 49, 51, 52, 54, 55, 57, 58, 60, 61, 63, 64, 66, 
68, and 70 The schedule of procedures was 
updated to reflect the weekly 
platelet monitoring and removal 
of duplicate platelet collection. 
Appendix B List of Laboratory Analytes  Added: 
Total IgG 
Total IgM Added two new laboratory 
analytes. 
 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
14  PROTOCOL SYNOPSIS  
Protocol Title  A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Assess the 
Efficacy and Safety  of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy 
(FAP) 
Study Phase  Phase 2/3  
Indication  Familial Amyloid Polyneuropathy  
Primary Objective s To evaluate the efficacy of ISIS 420915 as compared to placebo, given for 
65 weeks , as measured by the change from baseline in the modified Neuropathy  
Impairment Score +7 (mNIS+7)  and in the Norfolk Quality of Life-Diabetic 
Neuropathy (Norfolk QOL-DN) questionnaire total score, in patients with FAP  
Secondary Objectives  To evaluate the efficacy of ISIS 420915 as compared to placebo, based on the 
change from baseline in the following measures:  
1. Norfolk QOL -DN questionnaire symptom s domain score in Stage 1 patients 
and Norfolk QOL-DN questionnaire physical functioning/large fiber neuropathy 
domain score in Stage 2 patients  
2. Modified body mass i ndex (mBMI) and body mass index ( BMI) 
3. NIS and modified +7  
4. NIS+7  
5. Global longitudinal strain  (GLS) by echocardiogram (ECHO)  in the ECHO 
subgroup and in the Cardiomyopathy -ECHO (CM -ECHO) Set 
To evaluate the pharmacodynamic  (PD) effect of ISIS  420915 as compared to 
placebo, based on the change from baseline in transthyretin ( TTR) and retinol 
binding protein 4 (RBP4) . 
To evaluate the safety and tolerability of ISIS  420915. 
To evaluate the plasma trough levels of ISIS  420915 in all patients and to evaluate 
the plasma pharmacokinetic parameters of ISIS  420915 in a subset of patients . 
Tertiary Objective s To evaluate the change from baseline as compared to placebo in the following 
measures : 
• SF-36 questionnaire  
• Individual components of NIS, modified +7, and +7  
• +7 
• Individual domain scores of the Norfolk QOL- DN questionnaire  
Exploratory Objectives  To evaluate the change from baseline as compared to placebo in the following 
exploratory measures: 
• ECHO  parameters  (except GLS ) in the ECHO subgroup and in the CM -ECHO 
Set 
• Plasma N -terminal prohormone of brain natriuretic peptide  
(NT-proBNP) 
• Polyneuropathy disability score (PND)  
• Neuropathy symptoms and change (NSC)  score 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
15  Protocol Synopsis Continued  
Study Design  Multicentre, randomized, double- blind, placebo-controlled study.  Approximately 
135 patients will be randomized in a 2:1 ratio ( 90 ISIS 420915 and 45 PBO) to 
receive 300 mg ISIS 420915 or placebo.  Study Drug ( ISIS 420915 or placebo) will 
be administered 3 times on alternate days during Week 1 (Days 1, 3 and 5), and 
then once weekly during Weeks 2-65 (for a total of 67 doses).  Patients will also 
receive daily supplemental doses of the recommended daily allowance of vitamin A.  
The end of treatment (EOT) efficacy assessment is conducted at Week 66.  
Following treatment and the EOT efficacy assessment, eligible p atients (including 
patients that received placebo),  may elect to enroll in an open-label extension (OLE) 
study pending study approval by the IRB/ IEC and the appropriate regulatory 
authority.   All participating patients in the OLE study will receive 300 mg ISIS  420915  
once weekly.  Patients  not participating in the OLE  will enter the 6-month 
post-treatment evaluation portion of this  study  after completing the EOT efficacy 
assessment. 
Number of Patients Approximately 135 patients will be enrolled into this study  
Study Population  Inclusion Criteria:  
1. Stage 1 and Stage 2 FAP patients with the following:  
a. NIS score ≥  10 and ≤ 130 
b. Documented transthyretin variant by genotyping  
c. Documented amyloid deposit by biopsy  
2. Willingness to take vitamin A supplements  
3. Aged 18 to 82 years old at the time of informed consent  
4. Satisfy the following:  
a. Females:  non- pregnant and non-lactating; surgically sterile, post -
menopausal, abstinent, or if engaged in sexual relations of child- bearing 
potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until at 
least 3 months after the last dose of Study Drug  
b. Males:  Surgically sterile, abstinent, or  if engaged in sexual relations  of 
child- bearing potential, patient is utilizing an acceptable contraceptive 
method (refer to Section 6.3.1 ) during and for 3 months after the last dose 
of Study Drug  
5. Must have given written informed consent (signed and dated) and any 
authorizations required by local law and be able to comply with all study 
requirements  
Exclusion Criteria:  
1. Unwillingnes s to comply with study procedures, including follow -up, as 
specified by this protocol, or unwillingness to cooperate fully with the Investigator  
2. Screening laboratory results as follows, or any other clinically-significant  
abnormalities in screening laboratory values that would render a patient 
unsuitable for inclusion:  
a. ALT/AST > 1.9 x ULN 
b. Bilirubin ≥ 1.5 x ULN (patients with bilirubin ≥  1.5 x ULN may be  allowed 
on study  following discussion with the Study Medical Monitor  if indirect 
bilirubin only is elevated, ALT/AST is not greater than the ULN and genetic 
testing confirming Gilbe rt’s disease) 
c. Platelets < 125 x 109/L 
d. Positive (≥  trace) for protein on urine dipstick.  In the event of a positive 
test eligibility may be confirmed by a quantitative total urine protein 
measur ement of <  1.0 g/24 hours 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
16  Protocol Synopsis Continued  
Study Population  Continued  Exclusion Criteria:  Continued  
e. Positive (≥ trace) for blood on urine dipstick.  In the event of a positive test 
eligibility may be confirmed with urine microscopy showing ≤  5 red blood 
cells per high power field.  If >  5 red blood cells per high power field and 
there is a clearly identifiable benign cause for the microscopic hematuria 
(for example chronic urinary tract infection secondary to neurogenic 
bladder) eligibility should be determined by discussion with the 
Study  Medical Monitor  
f. TSH values outside normal range (unless approved by the Study Medical  Monitor) 
3. Retinol level at Screen < LLN  
• For patients with a TTR mutation at position 84 (e.g., Ile84Ser or Ile84Asn) 
and retinol < LLN the exclusion criterion is signs or symptoms of vitamin A 
deficiency (such as evidence of vitamin A deficiency on ERG)  
4. Uncontrolled hypertension (blood pressure >  160/100)  
5. Positive test result for HIV, hepatitis B, or hepatitis C  
6. Karnofsky performance status ≤  50 
7. Renal insufficiency as defined by estimated creatinine clearance calculated 
according to the formula of CKD -EPI < 60 mL/min/1.73 m2 at Screen.  If the 
calculated creatinine clearance is thought to be artificially low, a 24- hour urine 
creatinine clearance can be completed with prior Sponsor approval 
8. Presence of known type 1 or type 2 diabetes mellitus  
9. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune 
disease)  
10. Treatment with another i nvestigational drug, biological agent, or dev ice within  
3 months  of Screening, or 5 half-lives of study agent, whichever is longer  
11. If previously treated with Vyndaqel®, must have discontinued treatment for 2 weeks prior to Study Day 1.  If previously treated with Diflunisal, must have 
discontinu ed treatment for 3 days prior to Study Day 1  
12. Previous treatment with any oligonucleotide or siRNA within 6 months of 
Screening.  Subjects that have been previously treated with oligonucleotides should be approved by the S tudy Medical Monitor  
13. Prior liver transplant or anticipated liver transplant within 1- yr of S creening  
14. New York Heart Association (NYHA) functional classification of ≥ 3 
15. Acute coronary syndrome or major surgery within 3 months of S creening  
16. Known Primary Amyloidosis  
17. Known Leptomeningeal Amyloidosis  
18. Anticipated survival less than 2 years  
19. Active infection requiring systemic antiviral or antimicrobial therapy that will not 
be completed prior to Study Day 1
 
20. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated. 
Patients with a history of other malignancies that have been curatively treated may be eligible but must be discussed and approved by the Sponsor Medical 
Monitor  
21. Have any other conditions, which, in the opinion of the Investigator would make the patient unsuitable for inclusion, or could interfere with the patient 
participating in or completing the study  
22. Known Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma  
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
17  Protocol Synopsis Continued  
Study Population  Continued  Exclusion Criteria : Continued  
Additional eligibility criteria for patients participating in the ECHO subgroup : 
1. Must have left ventricular wall thickness of ≥  13 mm on transthoracic 
echocardiogram at Baseline  
2. No known history of persistent hy pertension ≥ 150 mm Hg within 12 months 
prior to Screening  
3. Baseline ECHO is evaluable as ascertained by Sponsor central reader  
Treatment Groups  Patients will be randomized 2:1 to receive 300 mg ISIS  420915 or placebo  
Study D rug Product Dosage 
and Administration  Study D rug (ISIS  420915 300 mg or placebo) will be administered as  subcutaneous  
(SC) injections in the abdomen, thigh or upper arm  
Rationale for Dose and 
Schedule S election 300 mg administered 3 times during Week 1 and then once weekly was chosen 
based on the pharmacokinetic, pharmacodynamic and safety analysis of the 
ISIS 420915 Phase 1 study in healthy volunteers  
Study Visit Schedu le and 
Procedures  The study for an individual patient will generally consist of the following periods:  
• A ≤ 6-week screening and baseline assessment  period  
• A 65-week treatment period during which Study Drug will be administered as 
a once weekly SC injection (except during Week 1 where 3 SC injections will 
be given on alternate days)  
• A 1- week EOT efficacy assessment period, and  
• A 6-month post -treatment evaluation period  
Collection and measurement of vital signs, clinical laboratory parameters (including 
hemat ology, serum chemistry, and urinalysis ), adverse events, concomitant 
medication/procedure information, PD parameters (TTR and RBP4), ISIS  420915 
plasma trough concentrations, and immunogenicity testing will be performed 
according to the schedule of procedures in Appendix  A.  The following assessments 
will also be performed at specified visits during the study:  mNIS+7, Norfolk QOL-DN 
questionnaire, SF -36 questionnaire, physical examination, PND score, mB MI/BMI, 
Columbia-Suicide Severity Rating Scale (C -SSRS) questionnaire, ophthalmology 
examination, electroretinogra m (ERG), and electrocardiogram (ECG).  All patients 
will also have a baseline transthoracic ECHO conducted in the screening and baseline assessment period and Week 65 and patients participating in the ECHO 
subgroup will have a Week 41 ECHO.  In addition, approximately 30 patients will 
have additional pharmacokinetic, ECG, complement, coagulation, hematology, and 
inflammatory  testing at specified visits according to the schedule of procedures  
(Appendix A ). 
Study Drug will be administered at the Study Center during scheduled clinic visits as 
outlined in the schedule of procedures ( Appendix A ).  Otherwise, administration of 
Study Drug may be given by either the Study Center personnel or at home by the patient/caregiver.  Dosing instructions and training on injection technique will be 
provided to the patient where applicable.  
Safety and Tolerability 
Evaluations  The safety and tolerability of ISIS  420915 will be assessed on an ongoing basis by 
the Study Medical Monitor and by the Independent Data and Safety Monitoring 
Board (DSMB), as outlined in the Safety Monitoring Plan and DSMB Charter.  
Safety and tolerability assessments include: adverse events, vital signs, physical examination, clinical laboratory tests, 12 lead ECG, use of concomitant medications, 
ophthalmology exam ination, ERG exam ination, and C -SSRS questionnaire.  
 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
18  Protocol Synopsis Continued  
Efficacy Evaluations Efficacy evaluations include change from baseline in mNIS+7, Norfolk QOL-DN 
questionnaire, mBMI, BMI, and individual  components of mNIS+7, NIS+7 , and 
change in GLS  by ECHO   
Pharmacokinetic Evaluations  Plasma samples will be taken for measurement of ISIS  420915 trough and post -
distribution levels at the time points detailed in Appendix A  and Appendix  C.  In a 
subset of patients, more frequent assessment of pharmacokinetic parameters of 
ISIS 420915 will be determined as detailed in Appendix A and Appendix C.  
Pharmacodynamic 
Evaluations  Circulating levels of TTR and RBP4 will be determined throughout the study 
according to schedule of procedures  (Appendix A).  
Statistical Considerations The sample size for this study was estimated using published natural history  data 
(Adams et al. 2015) and efficacy data (Berk 2013; Adams 2015) reported in a similar 
patient population as that targeted in this protocol .  The calculations assume an 
effect size of 9.6 points  and standard deviation of 14 i n the mNIS+7 score, an effect 
size of 10.7 and standard deviation of 18 in the Norfolk QOL-DN total score, and a 
drop- out rate of 25% .  One hundred thirty -five ( 135) patients will give at least 90% 
and 80% power  in the mNIS+7 and Norfolk QOL-DN endpoints , respectively,  using a 
two-sided t -test with an alpha level of 0.05.  
Eligible patients will be randomized 2:1 (ISIS  420915 : PBO) and stratified for:  
• Previous treatment with Vyndaqel® (tafamidis) or Diflunisal versus no known 
previous treatment  
• Stage 1 versus Stage 2 disease 
• V30M TTR mutation versus non-V30M TTR mutation  
The study will enroll approximately 50% Stage 1 and 50% Stage 2 patients.  
An interim analysis of reduction in TTR level will be performed by an independent 
statistician and presented to the independent DSMB af ter approximately 45 patients 
have completed the Week 13 visit.  Details of the analysis and controlled access to the unblinded data are outlined in the Statistical Analysis Plan (SAP)  and DSMB 
Charter . 
The primary endpoint s are the change in the mNIS+7 sc ore and the change in the 
Norfolk QOL -DN questionnaire total score from baseline to Week 66.   The 2 primary 
endpoints will be analyzed using a ranking strategy with the mNIS+7 tested first and 
the Norfolk QOL-DN questionnaire total score tested second.  Interpretation will be 
made in a stepwise approach, i.e. should the null hypothesis for the mNIS+7 be 
rejected, then the null hypothesis for the Norfolk QOL-DN will be tested.  However, if 
the null hypothesis for the mNIS+7 is not rejected, testing for the N orfolk QOL -DN 
will be considered exploratory.  No adjustment will be made for multiple testing (both endpoints will be tested at an alpha of 0.05). Various sensitivity analyses will be 
conducted to assess the impacts of the stratification factors and the missing values . 
Sponsor  Ionis  Pharmaceuticals, Inc.  
 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
19  STUDY DESIGN AND TREATMENT SCHEMA 
 
A An exception to the 6-week period given to perform the screening evaluations and baseline assessments is the 
TTR genotyping and amyloid biopsy tests .  These tests  may be conducted up to 10 weeks prior to Study Day 1 .  
They are  only conducted if appropriate documentation is not already available.   In addition, ERG and 
ophthalmology examinations may be conducted up to 1- week  after Study Day 1 if needed for scheduling 
purposes  (except for Ile84 patients that fall under exclusion criteria 3 and should have eye examinations 
performe d to determine  eligibility) . 
B Patients that terminate treatment early should have the early termination visit and EOT efficacy assessments 
conducted ideally within 14 days from the last dose of Study Drug.   They should then enter the post- treatment 
evaluation period.   
Patients that discontinue treatment due t o live r transplantation should return to the clinic  for the EOT efficacy 
assessment as soon  as feasible after the transplant procedures  (if possible  within 6 weeks) .  After the early 
termination  and EOT efficacy assessment procedures are complete, the pati ent should be withdrawn from the study.   
TREATMENT PERIOD  
Week  1 to 65 
•Week 1:  3 SC doses of 
Study  Drug (Days 1, 3 and 5)  
•Weeks 2 -65:  Once weekly SC 
dose of Study Drug  
END OF TREATMENT EFFICACY 
ASSESSMENT  
Week 66  
POST -TREATMENT 
EVALUATION PERIOD  
6 months  
SCREEN and BASELINE 
ASSESSMENT PERIOD  
Week  -6 to -1A 
EARLY TERMINATION 
VISIT  
END OF TREATMENT EFFICACY 
ASSESSMENTB 
Treatment terminated but 
consent not withdrawn  
Patient 
terminates 
treatment 
early  
OPEN LABEL EXTENSION 
(OLE ) STUDY 
 
Eligible patients only and 
pending study approval by the 
IRB/IEC and appropriate 
regulatory authority 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
20  STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
+7 Sum 7 test.  Includes measurements of nerve conduction, vibration 
threshold and heart rate to deep breathing 
Alb/C ratio  Albumin/Creatinine ratio (performed on urine sample) 
aPTT Activated partial thromboplastin time  
ASO  Antisense oligonucleotide 
AUC  Area under the curve 
BMI  Body mass index 
CM Cardiomyopathy 
CM-ECHO Set  Patients with a diagnosis of TTR cardiomyopathy at study entry who are not in the ECHO subgroup, plus the patients in the ECHO subgroup 
C-SSRS  Columbia-suicide s everity rating s cale 
DSMB  Data and safety monitoring board 
ECG  Electrocardiogram  
ECHO  Echocardiogram 
ECHO Subgroup The subgroup of patients meeting protocol- specified ECHO criteria 
and having an additional e chocardiogram  assessment  
EOT  End of t reatment  
ERG  Electroretinogra m 
ET Early termination  
FAC  Familial amyloid cardiomyopathy 
FAP Familial amyloid polyneuropathy 
GLS  Global longitudinal strain 
ICH International c onference on harmonization  
IEC Independent e thics c ommittee  
IRB Institutional review board 
IXRS Interactive voice/web -response system  
LLN  Lower limit of normal 
mBMI  Modified body m ass index ( requires determination of plasma 
albumin levels; mBMI = BMI x serum albumin g/L) 
MMRM model  Mixed effect model with repeated measures  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
21  mNIS+7  Modified neuropathy i mpairment s core +7 .  Standar d NIS  but with 
modifications made to the +7 component 
Modified +7 +7 test with modifications made to the sensory and nerve 
conduction testing  
NIS Neuropathy impairment score  
NIS-LL Neuropathy i mpairment score- lower limb  
NIS+7  Neuropathy i mpairment s core +7  
Norfolk QOL- DN Norfolk quality of l ife-diabetic neuropathy questionnaire 
NT-proBNP  N-terminal prohormone of brain natriuretic peptide 
OLE  Open label extension 
OLTX  Orthotopic liver transplantation  
P/C ratio  Protein/Creatinine ratio (performed on urine sample)  
PD Pharmacodynamic 
PK Pharmacokinetic 
PND Score  Polyneuropathy disability score 
RDA  Recommended daily allowance 
RBP4  Retinol binding protein 4 
SAE  Serious adverse event  
SAP Statistical analysis plan  
SC Subcutaneous 
Study Day 1 Defined as the first day Study Drug is administered to the patient 
Study Drug ISIS 420915 or placebo  
SUSARs  Suspected unexpected serious adverse reactions  
TTR  Transthyretin  
TUCA  Tauroursodeoxycholic acid 
ULN  Upper limit of normal 
UTR  Untranslated region  
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
22  1. OBJECTIVES  
1.1 Primary Objective s 
To evaluate the efficacy of ISIS 420915 as compared to placebo, given for 65 weeks, as 
measured by the change from baseline in the modified Neuro pathy  Impairment Score +7  
(mNIS+7) and in the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL- DN) 
questionnaire total score , in patients with Familial Amyloid Polyneuropathy ( FAP). 
1.2 Secondary Objective s 
To evaluate the efficacy of ISIS 420915 as compared to placebo  based on the change from 
baseline in the following measures:  
• Norfolk QOL-DN questionnaire symptoms domain score in Stage 1 patients and Norfolk 
QOL -DN questionnaire physical functioning/large fiber neuropathy domain score in 
Stage 2 patients 
• Modified body mass index ( mBMI)  and body mass index ( BMI ) 
• NIS and modified +7  
• NIS+7 
• Global longitudinal strain  (GLS)  by echocardiogram (ECHO) in the ECHO subgroup and 
in the Cardiomyopathy- ECHO (CM -ECHO) Set  
To eval uate the pharmacodynamic  (PD)  effect  of ISIS 420915 as compared to placebo , based on 
the change from baseline in transthyretin (TTR ) and retinol binding protein 4 (RBP4). 
To evaluate the safety and tolerability of ISIS  420915. 
To evaluate the plasma trough leve ls of ISIS  420915 in all patients and to evaluate the plasma 
pharmacokinetic parameters of ISIS  420915 in a subset of patien ts. 
1.3 Tertiary Objectives 
To evaluate the change from baseline as compared to placebo  in the following measures: 
• SF-36 questionnaire 
• Individual components of NIS, modified  +7, and +7  
• + 7 
• Individual domain scores of the Norfolk QOL- DN questionnaire 
1.4 Explorator y Objectives  
To evaluate the change from baseline as compared to placebo , in the following exploratory 
biomarkers: 
• ECHO parameters (except GLS) in the ECHO subgroup and in the CM- ECHO Set  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
23  • Plasma N- terminal prohormone of brain natriuretic peptide (NT -proBNP ) 
• Polyneuropathy disability score (PND) 
• Neuropathy symptoms and change (NSC) score 
2. BACKGROUND AND RATIONALE  
2.1 Overview of Disease  
2.1.1 Transthyretin Amyloidosis  
Transthyretin is synthesized primarily in the liver and is secreted into the plasma as a 55 KD 
protein composed of 4 identical subunits of 14 KD each.  A major function of TTR in the plasma 
is to transport retinol (vitamin A) to tissues through an association with retinol binding protein 4 (RBP4 ).  Transthyretin amyloidosis is a rare hereditary disease caused by mutations in the TTR 
protein .  The disease causing mutations destabilize the normal tetrameric structure of TTR 
causing its dissociation into free monomers and subsequent aggregation into  insoluble fibril 
deposits .  These deposits are found in multiple organs including the peripheral nervous system, 
GI tract and heart.  They result in local damage to cells leading to a peripheral polyneuropathy  
(called Familial Amyloid Polyneuropathy or FAP) and a cardiomyopathy (called Familial Amyloid Cardiomyopathy or FAC). 
The main clinical manifestations of  FAP are progressive peripheral sensorimotor and autonomic 
neuropathy.  Sensory neuropathy starts in the lower extremities with paresthesias and 
hypoesthesias of the feet, followed within a few years by motor neuropathy (Sekijima  et al. 2009).  Gastrointestinal symptoms, characterized by diarrhea and weight loss can 
also be prominent and reflect  autonomic dysfunction ( Falk et al. 1997 ; Ando et al.  2005).  Death, 
on average, occurs within 10 years from symptom onset and is primarily due to malnutrition and cachexia,  cardiac disease, sudden death or renal failure  (Coelho et al. 2008).  FAP can be 
classified in to 3 stages of disease based on ambulatory status: Stage 1 – do not require assistance 
with ambulation; Stage 2 – require assistance with ambulation; Stage 3 – wheelchair bound 
(Coutinho et  al. 1980).   The total worldwide prevalence of FAP has been estimated at 
approximately 10,000 patients (Coelho et  al. 2008).  
Clinical trials in patients with FAP have used the Neuropathy Impairment Score (NIS), or 
derivatives of this score such as the NIS Lower Limb (NIS -LL) or the NIS +7, to assess 
progression of neuropathy.  The NIS score was originally developed for assessment of diabetic 
neuropathy and is a quantitative score of motor, sensory, and reflex function as judged by the clinician (Dyck  et al.  1991).  The NIS- LL is a subset of the full NIS and evaluates changes in  
motor, sensory and reflex activity specifically in the lower limbs whereas the full NIS also evaluates changes in the upper limbs and cranial nerves.  The NIS or NIS -LL scores are 
sometimes combined with the S um 7  Test (or  +7) to give the NIS +7 or NIS -LL+7 composite 
score ( Dyck  et al.  1997 ).  The  +7 Test is an objective score of large fiber function that includes 
measurements of nerve conduction, vibration threshold and heart rate to deep breathing (an assessment of autonomic function).  Thus the NIS +7 and NIS- LL+7  scores have the advantage of 
combining a subjective assessment scored by the clinician with objective measurements of autonomic and sensory nerve function, which are both affected in patients with  FAP.  The  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
24  NIS-LL / NIS- LL+7  score is most app ropriate to measure neuropathy progression in early  
Stage 1 FAP patients.  But patients in later Stage 1 and Stage 2 (as is the case for this protocol) 
can reach a ceiling effect on the NIS -LL score, and therefore the full NIS /NIS +7 is a more 
appropriate score for these patients.  However, even the NIS +7 may not be optimally sensitive 
for assessment of progression of neuropathy in the target population of this study because it is primarily focused on motor function and on large nerve fibers whereas FAP ha s a significant 
sensory component and affects both large and small nerve fibers, with a great deal of between patient heterogeneity in the degree to which the different nerve fiber types are affected (Plante -Bordeneuve et al. 2007).  Therefore in this stud y progression of neuropathy will be 
assessed using a modified NIS+7  score (mNIS+7 ), which includes a greater sensory component 
and assesses both large and small nerve fiber function.  During  the mNIS +7 assessment , the 
standard NIS +7 assessment  will also be collected and the NIS +7 will be analyzed as  a secondary 
endpoint.  The NIS score will be used for selection of the target population (inclusion criteria) because there is a greater body of data correlating NIS score with stage of disease.   The 
neuropathy symptom and change (NSC) score is a physician administered questionnaire  of the 
patient ’s neuropathy symptoms.  It is  collected during t he NIS assessment procedure and  will be  
analyzed  as an exploratory endpoint. 
The Norfolk Quality of Life-Diabetic Neuropathy ( Norfolk QOL -DN) questionnaire is  included 
to assess disease specific changes in the patient s’ perceived quality of life.  This instrument is a 
nerve fiber- specific, 5-domain tool that has been  validated in FAP patients ( Vinik et al. 2011).  
In addition, the SF-36 questionnaire is included as a non- disease specific  tool to assess the 
patient’s  perceived functional health and well- being . 
In FAC patients, TTR amyloid fibrils infiltrate the myocardium, with resultant diastolic dysfunction progressing to restrictive cardiomyopathy and heart failure.  The age of onset in FAC patients is between 60 and 70 years and the mean life expectancy from symptom onset is 5-6 years.  There is no widely accepted method for measuring progression of cardia c disease in 
FAC. However , recent studies have shown that strain imaging with echocardiography or MRI 
can detect changes within a 1 -year time frame ( Benson et al.  2011; Falk 2011).  I n addition, the 
cardiac biomarker N-terminal prohormone of brain natriuretic peptide  (NT pro -BNP) has been 
shown to be elevated in patients with cardiac amyloidosis due to Primary Amyloidosis  and to 
decline as cardiac function improves following removal of the amyloid forming light chain protein with chemotherapy (Palla dini et al. 2006).  In this study serum NT -proBNP will be 
assessed as an exploratory endpoint in all patients .  One (1) of the more sensitive ECHO 
parameters, global longitudinal strain, will be assessed as a secondary endpoint.  This analysis will be conducted in a subgroup of patients with echocardiographic evidence of cardiac amyloidosis (the ECHO subgroup) and in a subset of patients defined as the CM- ECHO Set.  
The CM -ECHO Set includes patients with a diagnosis of TTR cardiomyopathy at study entry 
who are not in the ECHO subgroup, plus the patients in the ECHO subgroup.  Other ECHO parameters will be assessed as exploratory endpoints.  
2.1.2 Current Therapies  
One (1) therapeutic strategy for FAP is orthotopic liver transplantation ( OLTX) since most of the 
amyloidogenic mutated TTR is secreted by the liver.  OLTX results in rapid disappearance of mutant TTR protein from the serum, although wild-type TTR protein continues to be produced 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
25  by the donor liver and can continue to deposit in the tissues after transplantation  (see 
Section  2.4).  The result is that OLT28 May  slow the rate of progression of peripheral and/or 
autonomic neuropathy but usually does not arrest the disease.  OLTX is per formed on about 
120 FAP patients worldwide each year ( results from the Familial  Amyloid Polyneuropathy 
World Transplant Registry).  Based on prognostic data after liver transplant, current practice is 
not to perform OLTX on patients with mBMI < 600 or in patients with cardiac involvement.  Additionally,  it has been observed that poorer prognosis is associated with non-V30M mutations, 
patients with late onset of disease ( > 50 years) or disease duration > 7 years.  Therefore, OLTX 
is generally limited to younger patients early in disease with mild symptoms (typically Stage 1) (Herlenius  et al. 2004 ; Stangou and Hawkins 2004; Okamoto et al. 2009 ). 
In November 2011, the first medication for FAP, Vyndaqel
® (tafamidis) , was approved under 
exceptional circumstances in the EU.  Vyndaqel® is indicated  in the EU for the treatment of 
transthyretin amyloidosis in adult patients with Stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment ( Coelho et al. 2012). 
2.2 T herapeutic Rationale  
ISIS 420915 is an antisense drug targeted to human TTR mRNA and its hybridization to the 
cognate TTR mRNA results in the RNase H -mediated degradation of the TTR mRNA, thus 
preventing production of the TTR protein (see Section 2.3 ).  ISIS  420915 was designed such that 
it would not hybridize to any other known human gene.  The strategy of treating FAP patients with ISIS  420915 is to reduce the levels of mutated and wild -type TTR protein secreted by the 
liver, a primary organ for antisense oligonuc leotide ( ASO) distribution after systemic delivery.  
It should be noted that ASOs are highly charged hydrophilic molecules that do not cross the blood brain barrier ( Levin et al. 2008 ) and thus systemic treatment with ISIS  420915 is not 
predicted to decrea se levels of TTR in the brain.   It is predicted that decreasing the amount of 
liver- derived TTR protein circulating in the plasma by treatment with ISIS  420915 will result in 
a decrease in the formation of TTR  amyloid fibril deposits, and thus slow or halt disease 
progression.  This strategy is a similar strategy to OLTX, with the exception that ISIS  420915 
reduces wild -type protein in addition to the mutated protein.  Given that wild- type TTR can 
continue to deposit as amyloid after liver transplant, this distinction may represent a therapeutic advantage. 
There is  a high unmet medical need  for both Stage 1 and Stage 2  FAP patients  world -wide.  For 
Stage 2 patients, there is currently no approved therapy and these patients are often not 
candidates for liver transplant due to advanced age, health reasons, or cardiac involvement.  For Stage 1 patients, Vyndaqel
® is currently  the only approved therapy.  However, it is only 
approved in some countries and is not yet widely reimbursed or established as the standard of care.  For  these reasons, it is appropriate to utilize a placebo control in this  Phase 2/3 study. 
Because TTR binds the retinol -RBP4 complex and prevents its excretion by the kidney, 
decreased plasma TTR levels result in d ecreased circul ating levels of both RBP4 and retinol.  
This has been shown with the naturally occurring TTR Ile84 mutation that disrupts the TTR-RBP4 -retinol complex and results in low plasma levels of retinol ( Waits et al. 1995 ).  Prolonged 
reduction of c irculating retinol could result in impaired delivery of retinol to peripheral tissues 
and consequent signs and symptoms of vitamin A deficiency such as night blindness, xerophthalmia or retinopathy.  However, chylomicrons are believed to provide an alterna tive 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
26  route of delivery of retinyl esters to peripheral tissues ( Wei et al. 1995) and chylomicron-
delivered retin yl will not be affected by treatment with ISIS 420915.  Indeed, preclini cal studies 
utilizing TTR null mice have shown that although the mice have only 5- 7% of circulating retinol 
and RBP4 levels compared to wild-type mice,  they are viable and fertile, and do not show any 
observable symptoms of vitamin A deficiency ( Episkopou et al. 1993; Wei et al. 1995).  In 
addition, the levels of retinol within tissues such as the liver, kidney, testis and eye were similar in the TTR null mouse compared with wild- type controls (Wei et al. 1995).  Furthermore, the 
retinal anatomy and function in these mice has been examined in detail with little effect found on the retinal structure or function (Bui  et al. 2001 ).  This is consistent  with the findings in the 
ISIS 420915 chronic monkeys studies where, after 9 months of repeat dosing, no signs of 
vitamin A deficiency were observed during the ophthalmic examination and histological evaluation of eyes, which included full view examination of the cornea, lens, sclera with attached conjunctiva, anterior and posterior chambers, retina and optic nerve.  In addition, twins have been reported in the literature that have a genetic mutation in RBP4 that causes their RBP4 
protein levels to be below the lower limit of quantification and also results in  very low plasma 
retinol levels ( Biesalski et al. 1999 ).  Although the twins presented with night blindness their 
symptoms re sponded to dietary manipulation to ensure adequate dietary vitamin A.  Taken 
together these findings imply that RBP4 is not essential for maintaining adequate tissue retinol levels.   To address the potential for impaired retinol delivery to tissues, in this study all patients 
will be required to take oral supplementation of the recommended daily allowance ( RDA) of 
vitamin A (approximately 3000 IU vitamin A per day).  In addition, an ophthalmic examination will be performed at Baseline, after approximately 7 months of treatment, and at the end of treatment.  An electroretinogram (ERG)  will also be performed at B aseline and at the end of 
treatment to exclude subclinical tissue retinol defi ciency.  
2.3 ISIS  420915 
2.3.1 Mechanism of Action  
ISIS 420915 is a secon d-generation ASO  drug targeted to transthyretin .  It is complementary to a 
region within the 3′  untranslated region (3′ UTR) of the transthyretin mRNA and binds to the 
mRNA by Watson and Crick base pairing.  The hybridization (binding) of ISIS  420915 to the 
cognate mRNA results in the RNase H -mediated degradation of the transthyretin  mRNA, thus 
preventing production of the transthyretin  protein.  Maximal antisense- mediated reduction of 
targe t mRNA levels is typically greater  than 90%  of control levels in sensitive tissues 
(Crooke and Bennett 1996; Zhang et al . 2010).  Furthermore, reduction in target mRNA levels 
using this approach correlates directly  with a subsequent reduction in target protein levels.  
2.3.2 Chemistry  
Chemically, ISIS 420915 is a synt hetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by phosphorothioate linkages.  The nucleotide sequence of ISIS  420915 
(Figure 1 ) is complementary to a  20-nucleotide stretch within the 3′UTR region of the 
transthyretin  protein mRNA.  Structurally, the oligonucleotide has 3 regions.  Two (2) of them, 
the 5 nucleot ides at the 5 ′ end and the 5 nucleotides at the 3 ′ end, are composed of  
2′-O-(2-methoxyethyl) (MOE) -modified ribonucleotides.  These MOE-modified nucleotides 
confer (1) increased affinity to the target mRNA (Altmann  et al.  1996; McKay et al. 1999), 
(2) increased resistance to exonucleases and endonucleases (thereby increasing stability in tissue) 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
27  (Geary et al.  2003), and (3) amelioration of some of the high dose toxicities thereby resulting in 
an improved safety profile compared to first generation antisense drugs containing 
phosphorothioate modified oligodeoxynucleotides (DNA) ( Henry et al. 2000).  The third region, 
the central portion of the oligo nucleotide, is composed of 10 oligodeoxynucleotides .  This 
chimeric design is called a MOE -Gapmer, and ISIS  420915 employs this chimeric structure to 
enable use of the RNase H -mechanism for antisense activity.  This is because while the 2 ′-MOE 
modification confers increased stability and  affinity, it does not support RNase H catalysis of 
RNA hybridized to 2 ′-MOE -modified nucleotides ( McKay  et al. 1999).   This is caused by 
conformational changes i nduced in the heteroduplex by 2'-alkoxy:RNA hybrids that are not 
recognized by RNase H enzymes ( Inoue et al. 1987; Monia et al. 1993 ).  By limiting the 2 ′-MOE 
modification to nucleotides flanking the phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2 ′-MOE chemistry are preserved while also retaining RNase H 
recognition. 
 
Figure 1 Design of Chimeric 2 ʹ-MOE Phosphorothioate Oligonucleotides   
(MOE -Gapmer).  The sequence of ISIS  420915 is shown  
 
2.3.3 Preclinical Experience  
Detailed information concerning the preclinical studies conducted with ISIS 420915 can be 
found in the Investigator ’s Brochure.  A summary is included below. 
The nonclinical pharmacokinetics and toxicology evaluation of ISIS 420915 includes repeat dose 
studies up to 6 and 9 months in the CD -1 mouse and cynomolgus monkey, respectively .  
Nonclinical findings following ISIS 420915 treatment were, in general, non- specific class effects 
that are typical for 2′ -MOE ASOs ( Henry et al. 2008) and no findings were considered related to 
pharmacologic inhibition of TTR.  Cl ass effects occurred in a dose- and duration-dependent 
manner.  In the monkey they included transient effects on acute complement ac tivation (at doses 
≥ 10 mg/kg/wk) and acute elevations in activated partial thromboplastin time (aPTT) (at doses 
≥ 12 mg/kg/wk).  The changes in aPTT were not cumulative over the course of the 9-month 
monkey study.  In the mice, there was evidence of  inflammation that included the presence of 
minimal to moderate mononucl ear cell infiltrates in the  sinusoids of liver, lymph nodes and the 
subcuta neous injection site at doses ≥  40 mg/kg/wk after 3 and 6 months of treatment.  
Nonclinical pharmacokinetics ( PK) of ISIS  420915 was similar to other second-generation 
ASOs .  The ex posure of ISIS 420915 in plasma and tissue was dose-dependent.  T he majority of 
ISIS 420915 was cleared  from plasma within hours due mainly to distribution to tissues, with 
2′-MOE  
 2′-Deoxy  
 2′-MOE  
(RNase H  
- 
Sensitive)  
T  C  T   
T 
G  
G  T   
T 
A   
C 
A   
T 
G 
A   
A 
A 
T   
C 
C 
C 
Phosphorothioate  
Backbone  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
28  kidneys and liver having the highest concentrations.  The half- life in kidney and liver was 
approximately 13.5 days and 18.8 days, respectively, consistent with the plasma terminal 
elimination half -life of 17.0 days (at 8 mg/kg) after 4 doses. 
2.3.4 Clinical Experienc e 
Detailed information concerning the 1 clinical stud y (ISIS 420915- CS1)  conducted with 
ISIS 420915 can be found in the Investigator’s Brochure.  A summary is included below. 
ISIS 420915- CS1 was a Phase 1 double-blind, placebo-controlled, dose escalation study 
designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ISIS 420915 administered by subcutaneous injection to healthy subjects.  The study enrolled 65 healthy volunteers (16 in the single dose cohorts and 49 in the multiple dose cohorts).  Four (4) single dose levels (50, 100, 200, and 400 mg) and 5 multiple dose levels (50, 100, 200, 400 and 300 mg) were evaluated sequentially in the order listed .  The allocation of 
subjects was 3:1 or 8:2 randomized to ISIS 420915 or placebo in the single-dose or multiple -
dose cohorts, respectively.  Subjects enrolled in the multiple-dose cohorts received a total of 6 doses of Study Drug administered by SC injection:  3 doses on alternate days during the first week (Days 1, 3 and 5) and then once a week for the next 3 weeks (Days 8, 15 and 22).  
ISIS 420915 was well -tolerated  at the dose levels and dose regimens tested.  There were no 
serious adverse advents (SAE).  Two (2)  discontinuations were cons idered possibly related to 
ISIS 420915, 1 due to constitutional s ymptoms ( 400 mg subject)  and 1 due to injection site 
reactions ( 300 mg subject) .  The main safety findings included mild injection site reactions 
characterized most often by pain and erythema.  The duration of the reactions wer e typically 
24 hours and resulted from some but not all injections.  This injection site reaction profile is considered similar to the pr ofile for other 2′ -MOE ASOs.  Transient C -reactive protein 
elevations , primarily associated with the first injection, were observed in nearly all tr eated 
subjects at 200 mg multiple-dose or higher.  The peak elevations were generally observed 2 days after the first dose of ISIS 420915 (Study Day 3) and resolved within 2 weeks despite continued dosing.  For those subjects with C -reactive protein > 10 mg/L, the peak values at Day 3 had a 
median of 36 mg/L (range from 14 to 169 mg/L).  Retinol reductions below the lower limit of normal (LLN) occurred in approximately 50% of subjects treated in the  multiple -dose cohorts.  
The minimum retinol value was 0.19 mg/L (range 0.05 to 0.27 mg/L).  Recovery to above the LLN  occurred approximately 1-month after the final dose of ISIS 420915.  The retinol reduction 
was an expected consequence of TTR reduction.  
2.4 Rationale for Dose and Schedule of Administration  
The pharmacokinetics and disposition of many drugs in this class have been characterized and there are remarkable similarities from sequence to sequence and across species.  Because distribution to tissues is the dominant mechanism for plasma clearance, it  can be assumed that 
plasma pharmacokinetic similarities translate into similarities in tissue distribution.  This assumption is supported by the knowledge that patterns of tissue distribution for oligonucleotides are similar in mice, rats, rabbits, dogs and monkeys (and thus are expected to be similar in 
humans).  Additionally, ASOs are hydrophilic and distribute predominantly to the lean body mass and in our experience they should be administered as a fixed dose, rather than by total body weight. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
29  In FAP ( and FAC), both wild-type and mutant TTR protein will deposit in tissue as amyloid.  
However, it is not known what degree of reduction of TTR will be required to optimally 
attenuate progression of disease.  TTR mutant reductions ≥ 90% have been observed post- liver 
transplantation  (Adams et al. 2000 ) and have been shown to have a therapeutic effect.  Therefore, 
the therapeutic goal for ISIS 420915 is to reduce both wild- type and mutant plasma TTR levels 
as much as possible using a dose level that will not cause unacceptable toxicity.  Based on data from the TTR knock- out mouse (Episkopou et al. 1993) and from our 9-month chronic 
toxicology studies in non- human primates, significant target related toxicities are not anticipated 
even with near complete reduction of TTR.  In the ISIS 420915 Phase 1 study, the 300 mg dose level  showed a satisfactory safety profile and a substantia l pharmacodynamic effect after 6 doses 
(> 70% mean reduction in plasma TTR levels).  The PD  effect observed with the 300 mg dose 
level was also similar to that observed with  the 400 mg dose level , and therefore the 300 mg per 
week dose (with additional loading dose s in the first week) wa s selected for this Phase 2/3 study.  
Preliminary PK/PD modeling  (based on data from the Phase 1 study and extrapolation to steady-
state) predicts mean total (wild -type and mutant) TTR steady state reductions of ~80% with 
either a 300 mg/wk or 400 mg/wk regimen. 
A 65- week  (15-month) treatment period was selected for this study taking into consideration 
(1) the time needed to achieve steady -state TTR reductions with ISIS 420915 (~3 months) and 
(2) data reported for the tafamidis ( Vyndaqel
®) Phase 3 study, where a clear separation in 
progression of the NIS- LL score was not observed before  12 months of treatment  
(EMA Assessment report for Vyndaqel ). 
The safety data obtained in the ISIS 420915- CS1 study as well as the clinical experience with 
several other 2 ′-MOE -modified ASOs ( Sewell et al. 2002; Chi et al. 2005; Kastelein et al. 2006) 
supports the dosing regimen planned for this study .  The dosing schedule (load ing with 3 doses 
in Week 1 followed by once weekly SC injections) has been employed safely in previous clinical 
studies with a number of other phosphorothioate oligonucleotides at d oses well in excess of the 
300 mg dose utilized in this study.  Antisense oligonucleotides of this class have been safely administered intravenously and subcutaneously in multiple clinical stud ies at doses up to 
1000 mg (Kwoh 2008) and treatment duration’s ≥  6 months ( Chi et al 2008; Raal et al.  2010) and 
> 24 months ( Santos et al. 2012).  The safety and tolerability of the proposed 65-week dosing 
period is also supported by nonclinical chronic toxicology studies with ISIS 420915. 
3. EXPERIMENTAL PLAN  
3.1 Study Design 
This is a Phase 2/3 multicenter, double-blind, randomized, stratified, placebo-controlled study of 
ISIS 420915 in Stage 1 and Stage 2 FAP patients with a NIS score ≥  10 and ≤  130.  
Approximately 135 patients  will be ra ndomized 2:1 ( ISIS 420915 : PBO)  to receive 300 mg 
ISIS 420915 or placebo.  The study will enroll approximately 50% Stage 1 and 50% Stage 2 
patients.  Patients will be stratified for:  
• Previous treatment with Vyndaqel
® (tafamidis) or Diflunisal versus no known previous 
treatment 
• Stage 1 versus Stage 2 disease  
• V30M TTR mutation versus non-V30M TTR mutation 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
30  Patients will receive 3 SC  doses of Study Drug (ISIS 420195 or placebo) during Week 1 on 
alternate days (Days 1, 3 and 5) followed by once-weekly SC administration during Weeks 2-65 
(for a total of 67 doses).  
Approximately 20 patients at selected sites will be enrolled in a pharmacokinetic ( PK) subgroup 
and will receive  additional sampling for PK , ECG, complement, coagulation, inflammatory, and 
hematology as specified in the schedu le of procedures ( Appendix A ).  In addition, patients that 
are eligible may consent to participate in the ECHO subgroup and will receive an additional 
transthoracic ECHO during the treatment period ( Appendix A ). 
The end of treatment (EOT) efficacy assessment is conducted at Week 66  after which patients 
will enter the post- treatment evaluation period .  However,  following the EOT efficacy 
assessment, eligible patients (including patients that received  placebo)  may el ect to enroll in an 
open- label extension (OLE)  study pending study approval by the IRB/IEC and the appropriate 
regulatory authority.  A ll participating patients in the OLE study will receive once weekly doses 
of 300 mg ISIS 420915. 
3.2 Number of Study Centers  
This study will be conducted at mult iple centers worldwide.  
3.3 Number of Patient s 
Approximately 135 patients will be randomized in a 2:1 ratio (90 ISIS  420915 : 45 placebo).  
Any patient who initiated screening and met eligibility criteria at the time of Amendment 7 submission for applicable approvals may be enrolled into the study, even if 135 patients have already been randomized. 
3.4 Overall Study Duration and Follow- up 
This study will generally consist of the following periods: 
• A ≤ 6-week screening  and baseline assessment  period 
• A 65- week treatment period  
• A 1-week EOT efficacy assessment  period, and 
• A 6-month post- treatment evaluation period  
3.4.1 Screening  and Baseline  Assessment  
A period of 6 weeks is given to compl ete the screening and baseline assessments ou tlined in the 
schedule of procedures.  The baseline assessment s should ideally  be conducted after patient 
eligibility has been determined .  An exception to the 6- week screening and baseline assessment 
window is allowed for TTR genotyping and amyloid biopsy which may be conducted up to 
10 weeks prior to Study Day 1.  In addition, ERG and ophthalmology exam ination s may be 
conducted up to 1-week after Study Day 1 if needed for scheduling purposes (except for Ile84 patients that fall under exclusion criteria 3 and should have eye examinations performed to  
determin e eligibility). 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
31  3.4.2 Treatment  and EOT Efficacy Assessment  
The treatment and EOT efficacy assessment period comprise s approximately 66 weeks in total.  
Eligible p atients  will report to the Study Center for assessments at regular intervals throughout 
the 65- week treatment period .  During the treatment period, Study Drug is administered by SC 
injections  on alternate days during Week 1 (Days 1, 3 and 5), followed by once-weekly SC 
injections during Weeks 2-65. 
After the treatment period is complete, patients will report to the Study Center during Week 66 
for the EOT efficacy assessment s.  
3.4.3 Post-Treatment  
The post- treatment evaluation period is 6 months and consists of Study Center visits and 
additional safety testing .  The final study visit is Week 91. 
Alternatively, a fter completion of the EOT efficacy assessment period, eligible patients 
(including patients that received placebo) may elect to enroll in a n OLE  study where they will 
receive weekly doses of 300 mg ISIS  420915, pending study approval by the IRB/IEC and 
appropriate regulatory authority.   In this case, patients will not participate in the post -treatment 
evaluation period. 
3.5 End of Study  
The end of study is last patien t, last visit. 
3.6 Data Safety and Monitoring Board 
A Data and Safety Monitoring Board ( DSMB) will be assembled to review  safety , tolerability 
and efficacy (as needed)  data collected on ISIS 420915 during this study and  to review the 
results of the predetermine d TTR  interim analysi s (see Section  10.4).  Based on its ongoing 
assessment of the safety and tolerability  of ISIS 420915, the DSMB will  provide 
recommendations to the Sponsor for modifying, stopping or continuing the study as planned.  
Details on the safety assessments, frequency of review, meeting schedules and controlled access to unblinded data at the TTR interim analysis  are outlined in the DSMB Charter and SAP. 
4. PATIENT ENROLLMENT  
4.1 Screening  
Before patients may be en rolled  into the study, the Sponsor requires a copy of the Study Center ’s 
written independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, informed consent form, and all other patient information and/or recruitment material. 
Patients must sign the consent form  before any screening tests or assessments are performed.  At  
the time of consent the patient  will be considered enrolled into the s tudy and will be assigned a 
unique screening number before any study procedures, including screening procedures, are 
performed .  At the time of randomization patien ts will be assigned a unique patien t identification 
number.  This number will be used to identify the patien t throughout the trial and must be used 
on all study documentation related to that patien t.  The screening number and patient 
identification number must remain constant throughout the entire trial.  In the event the patien t is 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
32  re-consented and re -screened the patien t must be given a new screening number .  Screening 
numbers and patient identification numbers, once assigned, will not be re-used. 
4.2 Randomization 
Patient s will be randomized after all screening  and baseline assessments have been completed 
and after the Investigator has verified that they are eligible per criteria in Sections 5.1  and 5.2.  
No patient may begin treatment prior to randomization and assignment of a unique patient  
identification number. 
Using an Interactive Voice /Web -Response System (I XRS), eligible patients will be randomized 
2:1 to receive ISIS  420915 or placebo, respect ively .  There will be 2 separate and independent 
randomizations, 1 for patients in the PK subgroup (approximately 20 ) and 1 for the other patients 
who are not in the PK subgroup (approximately 115).  Within each randomization, patients will 
be stratified f or: 
• Previous treatment with Vyndaqel® or Diflunisal versus no known previous treatment 
• Stage 1 versus Stage 2 disease  
• V30M TTR mutation versus non-V30M TTR  mutation 
A permuted block schedule will be used  in both randomizations .  The Sponsor Q uality 
Assurance department or designee will hold a copy of the randomization lists generated by the IXRS vendor. 
4.3 Replacement of Patients 
Patients that withdraw from the study will not be replaced.  
4.4 Unblinding of Treatment Assignment  
The Sponsor, patien ts, monitors, and Study C enter  personnel will be blinded throughout the 
study until all patients have completed the treatment period and the EOT efficacy assessments, 
and the database has been locked.  The DSMB may be unblinded as described in Section 3.6.  In order to ensure maintenance of the study blind, TTR, RBP4, and retinol values will not be 
available to the Sponsor, monitors, Investigators, Study Center Personnel, or the patients .  
However, if a patien t has suffered a Serious Adverse Event (as defined  in Section  9.3.3), and/or 
when knowledge of the treatment assignment will impact the clinical management of the patien t, 
the Investigator will have the ability to unblind the treatment assignment for that  patien t using 
the IX RS.  The Sponsor or designee w ill be inform ed of the unblinding of a patient within 
24 hours.  In addition, all suspected unexpected serious adverse reactions ( SUSARs ) will be 
unblinded by the Sponsor’s Drug Safety and Quality Assurance personnel for the purpose of regulatory repor ting (see Section 9.2). 
Every reasonable attempt  should be made to complete the EOT efficacy assessment and early 
termination study visit procedures and observations (see Appendix A ) prior to unblinding, as 
knowledge of the trea tment arm could influence patien t assessment . 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
33  5. PATIENT ELIGIBILITY  
To be eligible to participate in this study candidates must meet the fo llowing eligibility criteria 
within 6 weeks  of Study Day 1, or at the time point specified in the individual eligibility criterion 
listed.  
5.1 Inclusion Criteria  
1. Stage 1 and Stage 2 FAP patients with the following: 
a. NIS score ≥  10 and ≤  130 
b. Documented transthyretin variant by genotyping 
c. Documented amyloid deposit by biopsy 
2. Willingness to take vitamin A supplements  
3. Aged 18 to 82 years old at the time of informed consent 
4. Satisfy the following: 
a. Females:  Non- pregnant and non- lactating ; surgically sterile, post-menopausal, 
abstinent, or if engaged in sexual relations of child -bearing potential, patient is using 
an acceptable contraceptive met hod (refer to Section 6.3.1) from the time of signing 
the informed consent form until at least 3 mo nths after the last dose of Study Drug 
b. Males:  Surgically sterile, abstinent , or if engaged in sexual relations of child-bearing 
potential, patient is utiliz ing an acceptable contraceptive method (refer to 
Section  6.3.1) during and for 3 mo nths afte r the last dose of Study Drug 
5. Must have given written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements  
5.2 Exclusion Criteria  
1. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator 
2. Screening laboratory results as follows, or any other clinically -significant abnormalities 
in screening laboratory values that would render a patient unsuitable for inclusion: 
a. ALT/AST > 1.9 x ULN  
b. Bilirubin ≥  1.5 x ULN (patients with bilirubin  ≥ 1.5 x ULN may be allowed on study 
following discussion with the Study Medical Monitor if indirect bilirubin  only is 
elevated , ALT/AST is not greater than the ULN  and genetic testing confirming 
Gilbe rt’s disease) 
c. Platelets < 125 x 10
9/L 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
34  d. Positive (≥  trace ) for protein on urine dipstick.  In the event of a positive test 
eligibility may be  confirmed  by a quantitative total urine protein measurement of 
< 1.0 g/24 hours 
e. Positive (≥  trace)  for blood on urine dipstick.  In the event of a positive test eligibility 
may be confirmed with urine microscopy showing ≤  5 red blood cells per high power 
field.  If > 5 red blood cells per high power field and there is a clearly identifiable 
benign cause for the microscopic hematuria (for example chronic urinary tract 
infection secondary to neurogenic bladder), eligibility should be determ ined by 
discussion with the Study Medical Monitor 
f. TSH values outside normal range (unless approved by the Study Medical Monitor) 
3. Retinol level at Screen  < LLN  
• For patients with a TTR mutation at position 84 (e.g., Ile84Ser or Ile84Asn) and 
retinol <  LLN the exclusion criterion is signs or symptoms of vitamin A deficiency  
(such as evidence of vitamin A deficiency on ERG) 
4. Uncontrolled hypertension (blood pressure > 160/100) 
5. Positive test result for  human immunodeficiency virus ( HIV) , hepatitis B or hepatiti s C 
6. Karnofsky performance status ≤ 50 
7. Renal insufficiency as defined by estimated creatinine clearance calculated according to 
the formula of CKD- EPI < 60 mL/min/1.73 m2 at Screen.  If the calculated creatinine 
clearance is thought to be artificially low, a 24- hour urine creatinine clearance can be 
completed with prior Sponsor approval 
8. Presence of k nown type 1 or type 2 diabetes mellitus 
9. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease) 
10. Treatment with another investigational d rug, biological agent, or device within 3 months 
of screening, or 5 half-lives of study agent, whichever is longer 
11. If previously treated with Vyndaqel® must have discontinued treatment for 2 weeks prior 
to Study Day 1.  If previously treated with Diflunisal, must have discontinued treatment 
for 3 days prior to Study Day 1 
12. Previous treatment with any oligonucleotide or siRNA within 6 months of screening.  Subjects that have been previously treated with oligonucleotides should be approved by the Study Medical  Monitor 
13. Prior liver transplant or anticipated liver transplant within  1 year of screening  
14. New York Heart Association (NYHA) functional classification of ≥  3 
15. Acute coronary syndrome or major surgery within 3 months of screening 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
35  16. Known  Primary Amyloidosis  
17. Known Leptomeningeal Amyloidosis  
18. Anticipated survival less than 2 years 
19. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day 1  
20. Malignancy within 5 years, except for basal or squamous cell carc inoma of the skin or 
carcinoma in situ  of the cervix that has been successfully  treated .  Patients with a history 
of other malignancies that have been curatively treated may be eligible but must be discussed and approved by the Sponsor Medical Monitor 
21. Have  any other conditions, which, in the opinion of the Investigator would make the 
patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study 
22. Known Monoclonal Gammopathy of Undetermined Significance or Multi ple Myeloma  
5.3 Additional Eligibility C riteria for Patients Participating in the ECHO S ubgroup 
1. Must have left ventricular wall thickness o f ≥ 13 mm on t ransthoracic echocardiogram at 
Baseline  
2. No known history of persistent hypertension ≥ 150 mm Hg within 12 months prior to 
screening  
3. Baseline ECHO is evaluable as ascertained by the Sponsor central reader 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A  and C . 
6.1.1 Screening  and Baseline Assessment Period  
Before any study- specific procedures or evaluations are initiated, patients must sign and date the 
informed consent form.  A 6-week period is given to perform the screening evaluations and 
baselines assessments which must be completed before Study Day 1.  Exceptions are the ERG, 
and ophthalmology examinations that may be conducted up to 1- week  after Study Day 1 if 
needed for scheduling purposes (except for Ile84 patients that fall under exclusion criteria 3 and should have eye examinations performed to  dete rmine  eligibility).  In addition, the TTR 
genotyping and amyloid biopsy tests may be conducted up to 10 weeks prior to Study Day 1.  These tests are only conducted if appropriate documentation is not already available.  The baseline assessments should idea lly be performed after patient eligibility has been determined.  
An abnormal screening result may be retested for review by the Study Medical Monitor for eligibility purposes.  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
36  A NIS assessment is performed at Screen ing to determine patient eligibility  only.  This 
assessment does not include the +7  components. 
The baseline assessments include mNIS+7  (which is performed twice), Norfolk QOL -DN 
questionnaire, transthoracic ECHO, 24 hour urine collection, ERG exam,  ophthalmology exam, 
vital signs, and a blood dr aw for chemistry . 
The 2 mNIS +7 assessments must  be performed on separate days and within 14 days prior to the 
first dose of Study Drug (Day 1).  In addition, every effort should be made to conduct the 
2 assessments < 7 days apart.  If the ERG or ophthalmology exam ination  are to be p erformed on 
a mNIS +7 assessment day, they must be performed after  the mNIS +7 assessment is complete.  
The mNIS +7 assessment  procedure includes the NIS, +7, and additional se nsory and nerve 
conduction testing.  The NSC s core is collected during the NIS assessment procedur e, but is 
analyzed separately.  
For a visit where the Norfolk QOL- DN questionnaire is to be administered, it must  be the first 
assessment performed at the visit .  Administration of the baseline Norfolk QOL -DN 
questionnaire should be done on the same day as the first mNIS +7 assessment, but prior  to the 
mNIS +7 assessment.  
For an individual patient, every effort should be made to ensure the same NIS evaluator performs 
all of the NIS assessments throughout the study.  In addition, the NIS evaluator must be insulated 
from the patient’s general study procedures and  knowledge of the patient’s adverse events. 
6.1.2 Treatment  Period  
During Study Week 1, patients will report to the Study Center for evaluations and Study Drug administration on Days 1, 3 and 5.  After Week 1, Study Drug will be administered once weekly.  Patients will report to the Study Center for Study Drug administration, evaluations, and tests 
regularly throughout the treatment period and wil l have weekly safety testing according to the 
Schedule of P rocedures in Appendix A .  During a c linic visit, all blood samples should be drawn 
prior to Study Drug administration (exceptions are the post-dose samples in the PK subgroup).  For weeks that do not include a clinic visit, Study Drug may be administered by either  Study 
Center personnel (in which case additi onal clinic visits will occur) or at home by the 
patient/caregiver (see Section 8.1 ).  Every effort should be made to ensure the previous week’s 
dose is  given 7 days prior to a scheduled clinic visit.  Dosing instructions and training will be 
provided to the patient where applicable. 
To help reduce patient travel burden, some clinic visits and weekly safety testing between visi ts 
may be done as non-clinic visits.  For non-clinic visits, collection of vital signs and labs (as 
indicated in the Schedule of Procedures) can be performed by the Sponsor’s home healthcare service or by a local laboratory with prior Spon sor approval. 
In addition to Study Drug, patients will also receive daily supplemental doses of the 
recommended daily allowance (RDA) of vitamin A ( approximately 3000 IU vitamin A or closest 
approximate dose as available in the region in which the patient resides).  Vitamin A may  be 
provided as either a single vitamin A supplement, or as part of a multivitamin .  The vitamin A 
supplement should be taken throughout the treatment and post- treatment evaluation period.  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
37  A mNIS+7 assessment and Norfolk QOL- DN questionnaire are conducted at Week 35  (D239) 
and must be conducted approximately > 24 hours from the previous week’s dose.  The  Norfolk 
QOL -DN questionnaire should be administered  prior to the mNIS +7 assessment .  The Week 35 
D239 and D240 assessments may be done on the same day. 
For Weeks 3 -15 there is a ± 2 day and  for Weeks 18-65 there is a ± 5 day visit window.  All 
reasonable attempts should be made to ensure compliance with the visit  schedule as outlined in 
the schedule of procedures ( Appendix A ).  However, in the event that a visit does not occur or is 
delayed , all subsequent visits should be calculated based on the time elapsed since Day 1 rather 
than from the date of the previous visit. 
During the treatment period, an ophthalmology examination will be performed at We ek 29 and 
Week 65, and an electroretinogra m (ERG)  examination will  be performed  at Week 65.  The 
Week 65 ophthalmology and ERG examinations may be done at Week 59 if needed for 
scheduling purposes.  A window of ± 2 week s is allowed  for the Week 29 and Week 65 (or 
Week 59) eye examinations.  
Patients with a TTR mutation at position 84 and with retinol levels < LLN at Screening , will be 
required to have 2 additional ophthalmology exam ination s at approximately 3 and 11 months 
after the first dose.  
Echoc ardiogram (ECHO)  Subgroup Only  
In addition to ECHOs conducted at B aseline, early termination, and Week 65 for all patients, 
patients who  qualify and consent to participate in the ECHO subgroup will have an  additional 
ECHO conduc ted during the treatment period at Week 4 1, which can be done at Week 47 if the 
patient elects to have a Home Healthcare visit at Week 41 .  All ECHO assessments have a 
window of ± 2 weeks. 
Pharmacokinetic  (PK)  Subgroup Only  
A subgroup of approximately 20 patients to ensure  approximately 15 patients with evaluable PK 
data a fter early withdrawals (at selected sites only), will participate in the PK subgroup.  Patients 
in this subgroup will have more frequent pharmacokinetic sampling in order to evaluate the 
plasma pharmacokinetic parameters of ISIS 420915.  Patients will also have additional post- dose 
sampling for ECG, inflammatory, coagulation, hematology, and compleme nt.  Patients in this 
subgroup will have additional visits to the clinic to collect  a 24 -hour post-dose blood draw after 
dosing on Day 1, and a 24 hour, 3 day and 7 post-dose blood draw after dosing on Day 240 (Week 35) and Day 449 ( Week 65).   Alternatively, the additional visi ts needed to collect the  
24 hour, 3 day and 7 day post-dose blood draw may be collected by the Sponsor appointed home healthcare service.  
A patient participating in either the PK or ECHO subgroups may withdraw consent for the subgroup specific procedures (e.g., echocardiogram, multiple blood draws for PK) without being withdrawn from dosing or from the study.  If a patient withdraws consent from the subgroup procedures, he/she should remain on study and continue to follow all the non -subgroup 
assessments an d procedures as outlined in Appendix A. 
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
38  6.1.3 EOT Efficacy Assessment Period 
The EOT efficacy assessment is conducted at Week 66 and consists of a minimum of 2 visits to 
allow for 2 measurements of the mNIS+7.  Both assessments must be performed on separate 
days and within 14 days from the last dose of Study Drug.  The first mNIS+7 assessment must be conducted approximately > 24 hours from the last dose of Study Drug.  In addition, every effort 
should be made to conduct the 2 assessmen ts < 7 days apart.  The Norfolk QOL-DN 
questionnaire should be given on the same day as the first mNIS+7 assessment, but prior to the 
mNIS+7 assessment. 
The Week 66 EOT efficacy assessment should also be performed on patients that terminate from 
treatment early.  In this case, the early termination visit and EOT efficacy assessment should be 
performed within 14 days after th e last dose of Study Drug.  In the event that this does not occur, 
the early termination visit and EOT assessments should be performed as soon as possible.  The 
2 mNIS+7 assessments must be conducted on separa te days.  In addition, every effort should be 
made to conduct the 2 assessments < 7 days apart. 
6.1.4 Post-Treatment Period 
After completion of the EOT efficacy assessment, patients will enter the 6-month post-treatment 
evaluation period and will report to the study cente r and have weekly platelet monitoring for a 
minimum of 6 weeks after the last dose of Study Drug which may be collected by the clinic, 
Sponsor’s home healthcare service or by a lo cal laboratory as outlined in the schedule of 
procedures ( Appendix A ).  At Week 71, adverse events shou ld be collected by the site personal 
through a phone contact with  the patient if a clinic visit was not conducted. 
Alternatively, after completion of the EOT effic acy assessment, eligible patients may elect to 
receive ISIS 420915 in an OLE study (ISIS  420915-CS3), pending study approval by the 
IRB/IEC and the appropriate regulatory authority.  In this case, patients will not participate in the 
post-treatment evaluation period bu t weekly platelet monitoring s hould continue between the last 
dose of Study Drug in CS2 and the first dose of  Study Drug in CS3.  If this period extends 
beyond 6 weeks, the frequency will be dete rmined by the Study Medical Monitor. 
6.2 Additional Study Assessments 
6.2.1 Laboratory Assessments 
Laboratory analyte samples will be collected throughout the study.  A list of these analytes is 
contained in Appendix B . 
6.2.2 Congestive Heart Failure 
Any patient that develops signs, symptoms or te st results suggestive of new onset or worsening 
(if pre-existing) congestive heart failure should have the following evaluations performed (in 
addition to any tests deemed to be necessary by the attending physician) as soon as possible and 
the Investigator should consider referral to a cardiologist: 
• Chest x-ray 
• 12 lead ECG 
• Echocardiogram 
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
39  In addition the Congestive Heart Failure supple mental CRF pages should be completed in the 
eCRF. 
6.2.3 Arrhythmias 
Any patient that develops signs, symptoms or te st results suggestive of  new cardiac arrhythmia 
should have the following evaluations performed (in addition to any tests deemed to be necessary 
by the attending physician) as soon as possible and the Investigator should consider referral to a 
cardiologist: 
• 12 lead ECG 
• Echocardiogram 
In addition the Arrhythmias supplemental CRF  pages should be completed in the eCRF. 
6.2.4 Myocardial Ischemia 
Any patient that develops signs, symptoms or te st results suggestive of  myocardial ischemia 
should have the following evaluations performed (in addition to any tests deemed to be necessary 
by the attending physician) and th e Investigator should consider referral to a cardiologist: 
• Serial 12 lead ECGs 
• Serial cardiac enzyme evaluation (CKMB,  cardiac troponin I or cardiac troponin T) 
In addition the Myocardial Infarction supplementa l CRF pages should be completed in the eCRF. 
6.2.5 Event-Specific Supplemental CRF Pages 
In the event of any of the following, the co rresponding supplemental CRF pages should be 
completed in the eCRF: 
• Death 
• Valvulopathy (i.e., signs, symptoms or test re sults suggestive of im pairment of function 
of 1 or more cardiac valves) 
• Deep vein thrombosis or pulmonary embolism 
• Peripheral arterial thromboembolism 
• Cerebrovascular event or transient ischemic attack 
• Revascularization 
• Pulmonary hypertension 
6.3 Restriction on the Li festyle of Patients 
6.3.1 Contraception Requirements 
All patients of childbearing potential must  refrain from sperm/egg donation and practice 
effective contraception from the time of signing the informed consent form until at least 
3 months  after their last dose of Study Drug. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
40  For the purposes of this study, women of childbearing potential are defined as any female who 
has experienced menarche, and that d oes not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤  55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and FSH levels in the postmeno pausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorecto my with or without hysterectomy 
• Post hysterectomy 
For the purposes of the study, effective contraception is defined as follows: 
For male patien ts: 
1. Effective male contraception includes a vasectomy with negative semen analysis at 
Follow-up, or the use of condoms together with spermicidal foam/gel/film/cream/ 
suppository.  Male patients must also encourage their female partner to use effective 
contraception from the time of signing the informed consent until 3 months after the  
patient ’s last dose of Study Drug.  Effective contraceptive for the female partner includes: 
surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterin e 
contraception/device, or barrier methods (female condom*, diaphragm, sponge, cervical cap) together with spermicidal foam/gel/film/cream/suppository .  Male patient s with 
partners that are pregnant must use condoms to ensure that the fetus i s not exposed to the 
Study Drug. 
For female patient s: 
2. Using 2 or more of the following acceptable methods of contraception: 
o  Surgical sterilization (e.g., bilateral tubal ligation) 
o Hormonal contraception  Oral contraceptive (either combined or progestogen alone) 
 Injectable progestogen 
 Implants of etonogestrel or levonorgestrel 
 Percutaneous contraception/device 
o Intrauterine contraception/device  
o Combination of male condom* with  female  diaphragm together with spermicidal 
foam/gel/ film/cream/suppository  
*Note : A female condom and a male condom should not be used together as friction 
between the 2 can result in either product failing  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
41  6.3.2 Other Requirements  
All patient s will be required to fast for at least 8  hours before a blood sample is taken for the 
pharmacodynamic and retinol assessments.  
7. STUDY DRUG  
7.1 ISIS  420915 or Placebo  
Study Drug ( ISIS 420915 or place bo) characteristics are listed in  Table 1. 
The Study Drug is contained in stoppered glass vials and will be provided to the Study Center by 
the Sponsor.  The Study Drug storage and preparation instructions will be provided by the Sponsor.  For long term s torage at clinical sites, t he Study Drug must be stored securely at 2° to 
8° Celsius and be protected from light. 
Table 1 Study Drug Characteristics  
Study Drug ISIS 420915  Placebo  
Strength 200 mg/mL  NA 
Volume/Formulation  1 mL solution per 2 mL vial  or 
1.5 mL solution per 3 mL vial   1 mL solution per 2 mL vial  or 
1.5 mL solution per 3 mL vial  
Route of Administration  SC 1.5 mL  SC 1.5 mL  
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with  packaged Study Drug labeled in accordance with 
specific country regulatory requirements. 7.3 Study  Drug Accountability  
The study staff is required to document the receipt, dispensing, and return  of Study Drug 
supplies provided by the Sponsor.  The Study C enter  must return all use d and unused Study Drug 
to the Sponsor or designee. 8. TREATMENT OF PATIENT S 
8.1 Study  Drug Administration  
For each individual patient, Study Drug will be administered subcutaneously as a single 1.5 mL 
injection 3 times in the first week and then once weekly  for Weeks 2 -65.  For weeks with a clinic 
visit, Study Drug will be administered at the clinic.  For weeks that do not include a clinic visit, 
Study Drug may be administered by either Study Center personnel or at home by the 
patient/caregiver.  Every effort should be made to ensure the previous week’s dose is given 
7 days prior to a scheduled clinic visit.  If Study Drug is to be administered at home, dosing instructions and training will be provided to the patient by the Study Center personnel. 
If needed for tolerability reasons, the single 1.5 mL injection may be adm inistered as 
2 noncontiguous injections of smaller volume, but prior discussion with the Study Medical 
Monitor is encouraged. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
42  Please refer to the Study Drug Manual  provided by the Sponsor for more detailed instructions for 
Study Drug preparation and admini stration.  
8.2 Other Protocol -Required Drugs  
All patients will take daily oral supplemental doses of the RDA of vitamin A ( approximately 
3000 IU vitamin A  or the closest approximate dose as available  in the region in which the patient 
resides).  Commercially available v itamin A as a single supplement, or as part of a multivitamin, 
will be provided by the Study Center or designee, in accordance with local regulatory 
requirements and availability. 
8.3 Other Protocol -Required Treatment Procedures  
There  are no other protocol required treatment proce dures. 
8.4 Treatment Precautions  
There are no specific treatment precautions required  for this study. 
8.5 Safety Monitoring Rules  
Please refer also to the ‘Guidance for Investigator’ section of the Invest igator’s Brochure . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
Confirmation Guidance :  At any time during the study (treatment or post- treatment periods), the 
initial clinical laboratory results meeting the safety monitoring  or stopping criteria presented 
below must be confirmed by performing measurements (ideally in the same laboratory that 
performed the initial measurement) on new specimens.  All new specimen collections should take place as soon as possible (ideally within 3 days of the initial collection). 
Stopping Rule Guidance:  In the event of an initial clinical laboratory result that meets a stopping 
criterion, patients must not be re-dosed until a confirmatory test result has been reviewed by the Study Medical Monitor.  If any of the stopping criteria described below (refer to Section s 8.6.1 
to 8.6.3) are met and are confirmed, the patient  will be permanently discontinued from further 
treatment with Study Drug ( ISIS 420915 or placebo), evaluated fully as outlined below and in 
consultation with the S tudy Medical Monitor  or appropriately qualified designee, and will be 
entered into the post- treatment evaluation portion of the study  (after completing the early 
termination and EOT efficacy assessments) .  In general, patients who do not meet the stopping 
rules based upon retest may continue dosing.  However, the Investigator and the S tudy Medical 
Monitor (or appropriately qualified designee) should confer as to whether additional close 
monitoring of the patient  is appropriate.  
Additional Guidance :  If possible, a pharmacokinetic sample should be collected as soon as 
possible after an SAE has occurred (preferably within 2 weeks).  In addition, if a patient is asked to return to the clinic for additional evaluations due to an AE, then a pharmacokineti c sample 
should be taken at the time of the unscheduled visit . 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
43  8.5.1 Safety Monitoring Rules fo r Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug-Induced Liver 
Injury: Premarketing Clinical Evaluation,” issued by the U.S. Department of Health and Human Services, Food and Drug Administration, July 2009. 
In the event of an A LT or AST measurement that is > 3 x ULN (or the greater of 2 x baseline 
value or 3 x ULN if the baseline value was > ULN ), at any time during the study (treatment or 
post-treatment period), the initial measurement(s) should be confirmed as described above.  
Similarly, confirmatory measurements should also be performed if ALT or AST levels increase to 5 x ULN.  
Frequency of Repeat Measurements:  Patient s wit h confirmed ALT or AST levels > 3 x ULN  (or 
the greater of 2  x baseline value or 3 x ULN if the baseline v alue was > ULN ), that are 
continuing to rise should have their liver chemistry tests (ALT, AST, ALP , INR and total 
bilirubin) retested at least once -weekly until levels stabilize and begin to recover (ALT and AST 
levels become ≤  1.2 x ULN or 1.2 x baseline value if the baseline value was > ULN ). 
Further Investigation into Liver Chemistry Elevations :  For patient s wit h confirmed ALT or AST 
levels > 3 x ULN  (or the greater of  2 x baseline value or 3 x ULN if the baseline value was 
> ULN), the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases  
2. Obtain further history for concomitant drug use (including nonprescription medications, herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets  
3. Obtain a history for exposure to environme ntal chemical agents and travel  
4. Total, direct and indirect bilirubin 
5. Serology for viral hepatitis (HAV IgM, HBsAg, HCV antibody, HCV mRNA, CMV IgM, and EBV antibody panel) 
6. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ ANA], antismooth muscle 
antibody, type 1 anti-liver kidney microsomal antibody) 
7. Serum acetaminophen -protein adducts by high pressure liquid chromatography if recent 
acetaminophen usage by patient  
Additional liver evaluations, including gastroenterology/hepatology consult ation s, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Study Medical Monitor.  Repetition of the above evaluations should be considered if a patient ’s ALT 
and/or AST levels reach 5 x ULN . 
8.5.2 Safety Monitoring Rules for Renal Function  
In the event of a confirmed (as described in Section 8.5) laboratory result meeting 1 or more of 
the following criteria, urinalysis (see Appendix B ) will be required approximately every 
2-3 weeks. * 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
44  a. Creatinine clearance by C KD-EPI < 60 mL/min/1.73m2 
b. Creatinine clearance by  CKD-EPI decrease from baseline** > 25% 
c. Urine Alb/C ratio >  5 x ULN  
d. Serum creatinine increase from baseline** > 0.5 mg/dL  
* urine collection should be performed at the same time as the protocol specified collection of 
serum creatinine (see Appendix A ) 
** baseline is Wk1D1 value 
In addition, the first confirmed result meeting a criterion (at any time on study) will trigger an 
immediate evaluation by a local nephrologist, ideally within 1- week .  The following labs should 
be obtained immediately:  fasting serum creatinine, urine cul ture, 24-hour urine sample for 
creatinine clearance and urine protein, and urine microscopy sample with nephrologist’s inspection of sediment.  Consideration of a dose pause (for example with a confirmed C KD-EPI 
decrease > 25%) should be discussed with the Study Medical Monitor.  A mandatory dose pause will occur with a 24 -hour urine protein result of >  2.0 g. 
If a patient remains stable over time they may be moved to less frequent monitoring of urinalysis at the discretion of the Study Medical Monitor in consultation with a neph rologist and the 
Investigator.  
If a patient meets a renal monitoring rule that is confirmed on repeat testing, the Investigator should review the patient’s concomitant medications for potentially nephrotoxic agents, and carefully con sider discontinuing non- essential medications.  Consultation with the Study Medical 
Monitor is encouraged.  
8.5.3 Safety Monitoring Rules for Ocular Effects  
All patients should receive an ophthalmology examination by an eye specialist at Baseline, after approximately 7  months of receiving Study Drug (Week 2 9) and also at the end of the dosing 
period (Week 65) .  An ERG will also be performed at Baseline and the end of the dosing period 
(Week 65).  In addition, any patient that complains of persistent ocular symptoms compatible with vitamin A deficiency (e.g., night blindness or dry eyes) should be referred for an ophthalmology examination.  If the ophthalmologist confirms the patient’s symptoms are consistent with vitamin A deficiency and/or the examination reveals physical findings that are 
consistent  with vitamin A deficiency  (but do not reach the stopping rule criteria described in 
Section 8.6.4) then an ERG examination should be conducted and analyzed by the central rea der.  
In addition, it is suggested that a review of diet and supplement use and an evaluation for factors which m ay contribute to  low vitamin A levels such as infection, alcohol consumption, and zinc 
and/or iron deficiency be conducted.  
If the ERG is changed from baseline and shows clear signs of vitamin A deficiency as assessed by the central reader and described below, then the patient should be monitored more frequently.  Frequency will be determined by the Sponsor Medical Monitor in consultation with th e 
Investigator and ophthalmologist. 
ISIS 420915-CS2 CONFIDENTIAL Amendment 9
Protocol 13 May 2016
 
45  Clear signs of vitamin A deficien cy as assessed by ERG include: 
a) Changes from baseline > 50%, and 
b) Values below normal range (if baseline va lues were within normal range), and 
c) Changes that are approximately symmetrical be tween eyes (unless ther e is an alternative 
explanation for asymmetry) 
Dosing with Study Drug may continue while these evaluations ar e being performed. 
8.5.4 Safety Monitoring Rules for Platelet Count Results 
Platelets will be monitored weekly throughout the treatment period a nd for a minimum of  
6 weeks after the last dose of  Study Drug (this includes early te rmination patients as well as 
patients that complete the full 65-week treatment period).  For patients participating in the Post-
Treatment Evaluation Period, frequency of testing after the Week 71 visit will be determined by 
the Investigator in cons ultation with the Study Medi cal Monitor.  For patient s participating in the 
ISIS 420915-CS3 study, weekly monitoring should continue between the last dose of Study Drug in CS2 and first dose of Study Drug in CS3.  If this period extends beyond 6 weeks, the frequency of monitoring will be determ ined by the Study Medical Monitor.  
All platelet count results must be promptly reviewed by the Inve stigator to ensure that the count 
has not met the stopping rule. 
If for any reason there is more than 14 days between platelet values (e.g., lab report of an 
unreadable sample due to clumping, hemolysis, or quantity not sufficient, or a missed lab 
assessment), the Investigator will contact the patie nt to hold dosing until a new platelet value is 
obtained and reviewed. 
If a patient’s platelet  counts fall below 100,000/mm
3, additional lab tests may be requested as 
determined by the Investigator in consultation with the Study Medical Monitor.  
8.6 Stopping Rules 
8.6.1 Stopping Rules for Liver Chemistry Elevations 
In the event of confirmed laboratory results meeting the following criteria, and the event is 
without an alternative explanation as di scussed with the St udy Medical Monitor,  dosing of 
a patient with Study Drug (ISIS 420915 or placebo) will be stopped permanently: 
1. ALT or AST > 8 x ULN 
2. ALT or AST > 5 x ULN at 2 consecutive weekly  measurements (not less than 7 days nor 
more than 10 days apart) both of whic h are confirmed.  Treatment with Study Drug 
(ISIS 420915 or placebo) may continue until  the second consecutive weekly ALT or AST 
measurement is confirmed to be > 5 x ULN 
3. ALT or AST > 3 x ULN and total bilirubin > 2 x ULN 
4. ALT or AST > 3 x ULN with the appearance  of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, ras h, and/or concomitant eosinophilia (> 5%) 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
46  8.6.2 Stopping Rules for Renal Function Test Results  
In the event of an estimated creatinine clearance by CKD -EPI meeting any of the following 
criteria, a serum creatinine and 24 -hour urine sample for creatinine clearance and protein should 
be obtained: 
• CKD- EPI d ecrease of > 50% from baseline 
• Value < 45 mL/min/1.73 m2 (if baseline CKD -EPI > 60 mL/min/1.73 m2) 
• Value < 30 mL/min/ 1.73 m2 (if baseline CKD -EPI ≤  60 mL/min/1.73 m2) 
Dosing of a patient with Study Drug (ISIS 420915 or placebo) will be stopped permanently if the 
24-hour urine testing confirms any of the following values in the absence of an alternative 
explanation agree by a consulting nephrologist : 
• urine protein is >  3.5 g 
• creatinine clearance < 45 mL/min/1.73 m2 (if baseline CKD -EPI >  60 mL/min/1.73 m2) 
• creatinine clearance < 30 mL/min/1.73 m2 (if baseline CKD -EPI ≤  60 mL/min/1.73 m2) 
Irrespective of whether the stopping rule is confirmed or not, the follow- up schedule and 
frequency of renal function monitoring after the initial event will be determined by the Study Medical Monitor in consultation with the Investigator and a rena l consult will be requested.  
8.6.3 Stopping Rule for Platelet Count Results  
In the event of a confirmed platelet count less than 75,000/mm
3, and in the presence of major 
bleeding or clinically -relevant  non- major bleeding  (defined below; Schulman et al. 2005), dosing 
of a patient with Study Drug (ISIS 420915 or placebo) will be stopped permanently.  The follow-up schedule for any events meeting this stopping criterion will be determined by the Investigator in consultation with the Study Medical Monitor. 
In the event of a confirmed platelet count less than 75,000/ mm
3, and in the absence of major 
bleeding or clinically -relevant  non- major  bleeding , further dosing of a patient with Study Drug 
(ISIS 420915 or placebo) must be held until the platelet count retur ns to at least 100,000/mm3.  
Weekly platelet monitoring should continue during this period.  In addition, the Investigator 
should give consideration to collecting duplicate platelet samples for study in a local lab in parallel to the central lab if it would provide quicker access to the patients platelet count.  If the platelet count was confirmed to be < 50,000/mm
3, then monitoring should be increased to daily 
until two successive values show improvement.  The In vestigator must notify the Study Medical 
Monitor within 24 hours of any local lab platelet results that show a level < 50,000/mm3. 
The su itability of the patient for continued dosing and the need for any modification to treatment 
schedule or dose (refer to Section 8.7) will be determined by the Investigator in consultation with 
the Study Medical Monitor and will be based on factors such as the original rate of decline in the patient’s platelet count, whether any bleeding events were experienced by the patient , and the 
speed of recovery of platelet count upon holding of dosing. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
47  Definition major bleeding events: 
International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding:  
1. Fatal bleeding, and/or  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or  
3. Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole blood or red cells 
Definition clinically -relevant , non- major bleeding events:  
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm
2 
3. Excessive wound hemato ma (not injection site related)  
4. Macroscopic hematuria (spontaneous or lasting > 24 hours if a ssociated with an 
intervention) 
5. Spontaneous rectal bleeding; epitasis, gingival bleeding, hemoptysis , hematemesis 
6. Bleeding after venipuncture for > 5 minutes  
8.6.4 Stopping Rule for Ocular Effects 
A patient should be permanently discontinued from Study Drug if an ERG is changed from 
baseline and shows clear signs of vitamin A deficiency (as described in Section 8.5.3) and an 
ophthalmology examination reveals significant changes from baseline in any 1 of certain physical signs ( Bitot’s sp ots, xerophthalmic ulcers, keratomalacia, or other signs and symptoms 
of corneal necrosis) and a consultation with the central reader has occurred. 
8.6.5 Stopping Rule for QTc Prolongation 
In the event of an ECG QTc value (average of triplicates) above the thresholds described below, 
repeat triplicate ECGs should be performed approximately 1 hour later and further dosing should be discussed with the Study Medical Monitor. 
• QTc > 500 msec (if baseline QTc ≤  470 msec) or 
• Increase in QTc value > 60 msec  from baseline (all patients)  
The suitability of th e patient for continued dosing, the need for any modification to treatment 
schedule or dose (refer to  Section 8.7) and the most appropriate follow-up schedule, will be 
determined by the Investigator in consultation with the Study Medical Monitor.  Suitability of continued dosing will be based on factors such as clinical symptoms, width of QRS complex, presence or absence of  paced rhythm, and the firing of a defibrillator (in the case that the patient 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
48  has an  implantable defibrillator).  In addition, consideration should be given to an expert 
cardiology read of the patients’ ECGs and a cardiology consult.  If a patient is deemed suitable 
for continued dosing, more frequent ECGs will be performed,  with the freq uency to be 
determined by the Investigator and Study Medical Monitor.  Any additional monitoring/investigation will also be determined by the Investigator and S tudy Medical Monitor.  
8.7 Adjustment of Dose and/or Treatment Schedule 
Adjustments of dose and/or treatment schedule should occur only on rare occasions.  Up to 2 adjustments in the treatment schedule may be allowed for patient s that are unable to tolerate 
the once weekly dose (for example if platelet counts fall below 75,000/mm
3 as described in 
Section  8.6.3).  Any proposed adjustment to treatment schedule or dose level must be discussed 
with, and approved by, the S tudy Medical Monitor prior to initiation.  If the patient remains 
stable after adjustment, they may be cautiously returned to the ori ginal dose/regimen after 
consultation with the S tudy Medical Monitor.  
Patients may be dose paused in response to adverse events after consultati on with Study Medical 
Monitor. 
8.8 Discontinuation of Study Treatment 
A patien t must permanently discontinue study treatment for any of the following: 
• The patien t becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patien t withdraws consent 
• The patien t experiences an adverse event that necessitates permanent discontinuation of 
study treatment 
• The patien t develops laboratory test abnormalities that meet any of  the stopping rules 
listed in  Section  8.6 
• The patien t experiences an AE that necessitates unblinding of the I nvestigator to the 
patient ’s treatment assignment  
The reason for discontinuation of study treatment must be recorded in the CRF and source 
documentation. 
Patients that discontinue from treatment are encouraged to remain in the study.  Every effort 
should be made to complete the early termination  visit and the  EOT efficacy assessment 
followed by all post- treatment evaluation visits.   If the patient declines to participate in the post -
treatment evaluation visits, at a minimum, the early terminat ion visit and EOT efficacy 
assessment proced ures should be performed at the time of withdrawal (See Appendix A ) and 
ideally within 14 days from the last dose of Study Drug.  If early termination assessments are to 
be performed on a day with mNIS +7 EOT assessment, the mNIS+7  assessment should be 
performed first.  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
49  8.9 Withdrawal of Patient s from the Study  
Patient s must be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
• Patient receives liver transplant  
Other reasons for withdrawal of patients from the study might include: 
• At the discretion of the Investigator for medical reasons  
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation 
• Administrative decision by the Investigator or Sponsor 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All information, including the reason for withdrawal from Study, must be record ed in the CRF . 
Any patien t who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  P atients withdra wn for 
any reason  should be encouraged to complete the EOT efficacy assessment and early termination 
study visit at the time of withdrawal ( Appendix A ). 
For patients who receive a liver transplant, every effort should be made to complete the EOT efficacy assessment as soon as feasible after the transplant procedures (if possible within 6 weeks).  After the EOT efficacy assessment and early termination visit is complete, patients should be withdrawn from the study. 
8.10 Concomitant Therapy  and Procedures  
The use of concomitant therapies or procedures defined below  must be recorded on the patient ’s 
CRF .  AEs related to administration of these therapies or procedures must also be documented on 
the appropriate CRF. 8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over- the-
counter medications, herbal medications and vitamin supplements) administered between signing 
of informed consent and Week 91 visit. 
Allowed Concomitant Therapy  
Any medications deemed necessary by the Investigator are allowed except those listed in the 
disallowed concomitant therapy. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
50  Disallowed Concomitant Therapy  
Patients are required to take daily RDA supplemental doses of vitamin A during the treatment 
and post- treatment evaluation period s.  The vitamin A supplements will be provided by the 
Study Center or designee.  A patient may choose to substitute the Study Center provided vitamin 
A supplement with their own, only after consultation wit h the Study Medical Monitor.   
Additional vitamin A supplements (other than those described above) are not allowed at any time during the study unless approved by the Study Medical Monitor (this includes multivitamin supplements that contain vitamin A).  
Doxycycline, and tauroursodeoxycholic acid (TUCA) are not allowed unless approved by the Study Medical Monitor.  If a patient is taking doxycycline or TUCA they should discontinue treatment at least 4 days pr ior to Stud y Day 1. 
Treatment with either Vyndaqel
® or Difluni sal is not allowed at any time during the treatment  
period and ideally should not be taken during the post- treatment follow -up period.  If Vyndaqel® 
or Diflunisal are taken in the post- treatment period, the Study Medical Monitor should be 
consulted to determine if an additional mNIS +7 assessment should be collected prior to initiating 
Vyndaqel® or Diflunisal  treatment.  
Due to known potential adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs), 
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) 
on renal function, it is recommended that they should be used with caution.  Discussion with the Sponsor Medical Monitor prior to initiation of drugs that may affect renal function is recommended.  
8.10.2 Concomi tant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between  
signing of informed consent and Week 91 visi t. 
8.11 Treatment Compliance  
Compliance with treatment dosing is to b e monitored and recorded by Study Center staff . 
The Study Center staff is required to document the receipt, dispensing, and return of Study Drug supplies.  Patients that are self -administering Study Drug at home must record treatment in a 
provided dosing diary that will be reviewed by the Study Center staff and Clinical Monitor. 
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  
9.1 Sponsor Review of Safety Information 
Safety informatio n will be  collected, reviewed, and eva luated  by the Sponsor in accordance with 
the Safety Management P lan throughout the conduct of the clinical trial.  
9.2 Regulatory Requirements 
The Sponsor is responsible for regulatory su bmissions and reporting to the Investigators of 
serious adverse events (SAEs) including SUSARs per the International Conference on 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
51  Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements 
will be followed in accordance with local country regulations and guidelines.  
IRB/IEC will be notified of any SAE according to applicable regulations.  The Data and Safety 
Monitoring Board (DSMB) will be notified of any SAE as specified in the DSMB  charter.  
The Sponsor  will evaluate the available information and decide if there is a reasonable possibility 
that the Study Drug caused the AE  and, therefore, meets the definition of a SUSAR. 
Appropriate personnel at the Sponsor  will unblind SUSARs for the purpose of regulatory 
reporting.  The Sponsor  will submit SUSARs to Regula tory Agencies in blinded or unblinded 
fashion according to local law.  The Sponsor will submit SUSARs to Investigators in a blinded 
fashion. 
For Study Drug “expected” events, refer to the Investigator Brochure.  
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically -significant 
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by the Study Drug. 
A suspected adverse reaction  is any adverse event for which there is a reasonable possibility that 
the drug caused the adverse event.  A suspected adverse reaction implies a lesser degree of certainty about causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening: that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the patient  at immediate risk of 
death.  It does not include an AE  or suspected adverse reaction that , had it occur red in a 
more severe form, might have caused death . 
• Requires inpatient hospitalization or prolongation of existing hospitalization  
Hospitalization is defined as an admission of greater than 24 hours to a medical facility and does not always qualify as an AE. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
52  • Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in congenital anomaly or birth defect in the offspring of the patient  (whether the 
patient  is male or female)  
• Important m edical events that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
interv ention to prevent 1 of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
9.4 Monitoring and Recording Adverse Events  
Any pre-existing conditions or signs and/or symptoms present in a patient prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that const itutes a  single unifying diagnosis  if possible.  
9.4.1 Serious Adverse Events  
In the interest of patient  safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event.  The collection of SAEs will 
begin after the patient signs the informed consent form and stop at the end of the patien t’s 
follow-up period which is defined as the Week 91  visit or  the EOT efficacy assessment for 
patients that will enroll into the OLE .  When  the Investigator is reporting by telephone, it is 
important to speak to someone in person versus leaving a message.   An Initial Serious Adverse 
Event Form should be completed and a copy should be faxed to the Sponsor or designee. 
Detailed information should be actively sought and included on Follow- Up Serious Adverse 
Event Forms as soon as additional information becomes available.   All SAEs will be followed 
until resolution .  SAEs that remain ongoing past the patient ’s last protocol -specified follow-up 
visit will be evaluated by the  Investigator and Sponsor.  If the Investigator and Sponsor agree the 
patient ’s condition is unlikely to resolve, the Investigator and Sponsor will determine the follow-
up requirement. 
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient signs the informed consent form 
and will stop at the end of the patien t’s follow-up period, which is defi ned as the Week 91 visit , 
or the EOT efficacy assessment for patient’s that will enroll into the OLE.   The Investigator will 
monitor each patient  closely and record all observed or volunteered AEs on the Adverse Event 
Case Report Form.  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
53  9.4.3 Evaluation of Adverse Events (Serious and Non -Serious)  
The Investigator’s opinion of the following should be documented on the Adverse Event Case 
Report Form: 
9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug is characterized by 1 of the following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug e.g., 
confirmation by positive re- challenge test  
• Possible:   The event cannot be explained by the patient ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to 
Study Drug administration and/or exposure suggests that a causal relationship  is unlikely 
(For reporting purposes, Unlikely/Remote will be grouped together with Not Related) 
• Not Related:  The ev ent can be readily explained by the  patient ’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug 
9.4.3.2 Severity  
The event’s severity is characterized by 1 of the following: 
• Mild:  The event is easily tolerated by the patient and does not affect the patient ’s usual 
daily activities  
• Moderate:   The event causes the patient more discomfort and interrupts the patient ’s 
usual daily activities  
• Severe:   The event is incapacitating and causes considerable interference with the 
patient’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria  must be indicated (criteria listed in 
Section 9.3.3 ). 
9.4.3.3 Action Taken with Study Drug  
Action taken with Study Drug due to the event is characterized by the following. 
• None:   No changes were made to Study Drug administration and dose  
• Permanently Discontinued:   Study Drug was discontinued and not restarted 
• Temporarily Interrupted, restarted:   Dosing was temporarily interrupted  or delayed 
due to the AE  and restarted  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
54  • Reduced dose:   Dosing was reduced  to a lower dose 
• Reduced schedule :  Dosing frequency was reduced  
9.4.3.4 Treatment Given for Adverse Event  
Any treatment (e.g., medications or procedures) given for the AE should be recorded on the 
Adverse Event Case Report Form ( treatment  should also be recorded on the concomitant 
treatment or ancillary procedures CRF  as appropriate ). 
9.4.3.5 Outcome of the Adverse E vent 
If the event is a non-serious AE then t he event’s outcome is charac terized by 1 of the following: 
• AE Persists:   Patient terminates from  the trial and the AE continues 
• Recovered:   Patient recovered completely from the AE  
• Became Serious:   The event became serio us (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity (if applicable):   AE severity changed  
If the event is a SAE then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non -serious AE eCRF (the 
SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution date)  
• Fatal:   Patient died (the date of death should be ente red as the SAE resolution date)  
9.5 Procedures for Handling Special Situations  
9.5.1 Abnormalities of Laboratory Tests 
Clinically -significant abnormal laboratory test results may, in the opinion of the Investigator, 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in pre ference to  abnormal labora tory values as AEs.  
Clinically -significant abnormalities will be monitored by the Investigator until the parameter 
returns to its baseline value or until agreement is reached between the Investigator and the Study Medical Monitor .  Laboratory abnormalities deemed not clinically -significant (NCS) by the 
Investigator should not be reported as AEs.  Similarly, laboratory abnormalities reported as AEs by the Investigator should not be deemed NCS on the laboratory sheet. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
55  The Investigat or is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source documents.  
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments 
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospitalized; the Study Center must document all of the following: 
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a wait ing list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study 
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opinion of the 
Investigator between the patient ’s consent to participate in the study and the timin g of the 
procedure or treatment 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospital admission 
9.5.3 Dosing Errors 
Study medication errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the patient  was symptomatic (list 
symptoms) or asymptomatic, and the event accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of Study Drug that exceeds protocol specifications and the patient  is symptomatic, then the 
symptom(s) should be documented as an AE  and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and  contact the Sponsor or designee within 
24 hours. 
9.5.4 Contraception and Pregnancy  
Male patients and female patient s of childbearing potential must continue to use appropriate 
contraception with their partners, or refrain from sexual activity, as described in Section 6.3.1. 
If a patient becomes pregnant or a pregnancy is suspected,  or if a male  patien t makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately .  An Initial Pregnancy Form should be submitted to the Sponsor or 
designee within 24 hours  of first learnin g of the occurrence of pregnancy.  Follow -up 
information including delivery or termination is reported on Follow-up Pregnancy Forms and reported within 24 hours. 
Payment for all aspects of obstetrical care, child or related care will be the patient ’s 
responsibility. 
Female patient s:  If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The patien t with a confirmed pregnancy will be immediately 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
56  withdrawn from treatment with Study Drug.  However, the patien t will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will assist the patien t in getting obstetrical care and the progress of the pregnancy will 
be followed until the outcome of the pregnancy is known  (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  
Male patient s:  The progress of the pregnancy in a male patien t’s partner should be followed 
until the outcome  of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, additional follow-up information may be requested for the mother and infant.  Follow- up will be performed  to the extent permitted  by 
applicable regulations and privacy considerations. 
10. STATISTICAL CONSIDER ATIONS  
10.1 Study Endpoints, Subsets, and Covariates  
10.1.1 Primary End points 
The primary endpoint s are the change in mNIS +7 score from baseline to Week 66  and the 
change in the Norfolk QOL-DN questionnaire total score from baseline to Week 66. 
10.1.2 Secondary Endpoints 
10.1.2.1 Secondary Efficacy Endpoints 
• Change in the Norfolk QOL-DN questionnaire symptom s domain score (Stage 1 patients 
only) and Norfolk QOL -DN questionnaire physical functioning/large fiber neuropathy 
domain score (Stage 2 patients only ) from baseline to Week 66  
• Change in the m BMI  and BMI from baseline to Week 6 5 
• Change in NIS and modified +7  from baseline to Week 66 
• Change in NIS +7  score from baseline to Week 66  
• Change in GLS  by ECHO from baseline to Week 65 in the ECHO subgroup and in the 
CM-ECHO Set 
10.1.2.2 Pharmacodynamic Endpoint 
• Change from ba seline in TTR  level  to Week 65 
• Change from baseline in RBP4 level to Week 65 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
57  10.1.2.3 Safety Endpoints 
• Adverse events 
• Vital signs and weight 
• Physical examination 
• Clinical laboratory tests  
• ECG  
• Use of concomitant medication  
• Ophthalmology and ERG examinations 
• Columbia- Suicide Severity Rating Scale  
• Thyroid panel 
• Inflammatory panel 
• Coagulation 
• Complement  
• Immunogenicity 
10.1.2.4 Pharmacokinetic Endpoints 
Selected ISIS 420915 post-distribution plasma concentrations (i.e., trough and various post-
treatment time  points) will be measured throughout the study and the estimated plasma terminal 
elimination half -life (t 1/2λz) after end of treatment will b e calculated (when possible).  In 
evaluable patients from the PK s ubgroup, additional selected plasma PK parameters (as outlined 
in Section 10.5.4) will also be determined after dosing on Days 1, 240, and 449.  Further details of the various planned plasma PK assessments are outlined in Section 10.5.4. 
10.1.3 Tertiary Endpoint 
• Change from baseline to Week 65 in SF-36 questionnaire domain scores 
• Change from baseline to Week 66 in the individual components of the NIS (cranial, muscle weakness, reflexes and sensory), modified  +7 (heart rate to deep breathing,  nerve 
conduction, heat -pain sensory and touch-pressure sensory testing), and +7  (vibration 
detection threshold and nerve conduction)  
• Change from baseline to Week 66 in +7  
• Change from baseline to Week 66 in individual domain scores of Norfolk QOL- DN 
(physical functioning/large fiber neuropathy, symptoms , activities of daily living, small 
fiber neuropathy and autonomic neuropathy) 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
58  10.1.4 Exploratory Endpoints 
• Change from baseline in echocardiogram  parameters (except GLS) in the ECHO 
subgroup and in the CM- ECHO Set  
• Change from baseline in NT -proBNP  
• Change from baseline in the PND score 
• Change from baseline in the NSC score 
• Change from baseline in retinol 
• Change from baseline in retinyl palmitate  
10.2 Sample Size Considerations  
The sample size for this study was estimated  using information published from the placebo 
controlled Phase 3 Diflunisal trial (Berk et al. 2013), a retrospective, multinational natural 
history study in 283 FAP patients ( Adams et al. 2015), and uncontrolled data using another TTR 
mRNA targeted therape utic (Adams  2015).   It is estimated  that the placebo group will have a  
16 point increase in the mNIS +7 score from baseline to Month 15, and the treated group will 
have a 6.4 point increase in mNIS +7.  The standard deviation of the change from baseline in 
each treatment group  is estimated to be 14.  With 135 patients  (2:1 allocation ratio) there  would 
be at least  90% p ower to detect a 9.6 point difference in the change from baseline in the mNIS+7 
score between the 2 groups, with a 2- sided t -test of 5% alpha, assuming that the dropout rate is 
approximately 25%.  
For the Norfolk QOL- DN questionnaire total score, it is  estimated that the placebo group will 
have a 13.3 point change from baseline to Month 15, the treated group will have a 2.6 point 
change from baseline and t he standard deviation of the change from baseline in each treatment 
group will be 18.  W ith 135 patients, there would  be at least  80% power to detect a 10.7 point 
difference in the change from  baseline in the Norfolk QOL total score between  the 2 groups, 
with a 2-sided 5% alpha, assuming that the dropout rate is approximately 25%.  
10.3 Populations  
The Full Analysis S et will include all randomized patients who received at least 1 injection of 
Study Drug (ISIS 420915 or placebo) and who have at least 1 post- baseline efficacy assessment 
for the mNI S+7 score or Norfolk QOL-DN questionnaire total score. 
The Safety Set will include all randomized patients who received at least 1 injection of 
Study Drug. 
The Per -Protocol Set will include the subset of the Full Analysis Set that have received at least a 
certain  percentage of the prescribed  doses of Study Drug and that have no significant protocol 
deviations that would be expected to affect efficacy assessments.  The detailed criteria will be 
specified and finalized prior to conducting the primary analysis (i.e. , exact criteria to determine 
inclusion in or excl usion from the Per Protocol Set will be determined for each patient prior to 
conducting the primary analysis ). 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
59  The Pharmacokinetic Set will include the subset of the Safety Set that has at least 1 evaluable PK 
result.  
The ECHO subgroup will include the subset of the Safety Set that has at least 1 evaluable post baseline ECHO assessment and participated in the ECHO substudy.  The CM- ECHO Set will 
include the subset of the Safety Set that has at least 1 evaluable post baseline ECHO assessment and had a diagnosis of TTR cardiomyopathy at study entry but are not in the ECHO subgroup, plus patients who participated in the ECHO subgroup. 
10.4 Interim Analysis 
A pharmacodynamic interim analysis of reduction in plasma TTR level will be performed  by the 
independent s tatistician  and reviewed by the DSMB after  approximately  45 patients have 
completed the Week 13 visit.  This interim will be  a futility analysis , so there  will be no 
statistical penalty assigned .  The results of this interim analysis will result in a decision to 
continue the study as planned or to stop the study.  Details of the analysis and controlled access 
to the unblinded data are outlined in the SAP  and DSMB Charter . 
10.5 Planned Methods of Ana lysis 
All eCRF data, lab data transfers, mNIS +7 score data, as well as any outcomes derived from the 
data, will be provided in the patient data listings.  Patient data listings will be presented for all 
patients enrolled into the study.  
Descriptive summary  statistics including n, mean, median, standard deviation, interquartile range 
(25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data  by 
treatment group .  Where appropriate, p-values will be reported.  All statistical tests will be 
conducted using 2- sided tests with 5% Type I error rates unless otherwise stated.  
All primary , secondary and tertiary efficacy  and pharmacodynamic endpoints , except GLS  will 
be assessed on the Full Analysis Set and Per -Protocol Set, with the former  being the basis for the 
primary efficacy analysis.  All safety assessments will be performed on the Safety Set.   PK 
endpoints will be assessed in the PK Set as applicable.   ECHO endpoints including GLS will be 
assessed in the ECHO subgroup and in the CM- ECHO Set.  
10.5.1 Demographic and Baseline Characteristics  
Demographic and baseline characteristics will be summarized using descriptive statistics by treatment group.  All patients enrolled will be included in a summary of patient disposition. 
10.5.2 Safety Analysis  
Treatment duration and amount of Study Drug received will be summarized by treatment group, 
as well as reasons for withdrawal from Study Drug . 
All treatment- emergent adverse events (AEs with onset after the first dose  of Study Drug) and 
serious adverse events will be summarized for each treatment group using the MedDRA
TM 
coding system, by system organ class, preferred term, relationship to Study Drug, and severity.  Narratives of deaths, serious adverse events, including early withdrawals from Study Drug and from study due to adverse events, will also be provided. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
60  Laboratory tests to ensure patient safety including chemistry panel, complete blood count with 
differential, coagulation panel, and complement, will be summarized by study visits for each 
treatment group.  These safety variables will also be presented as change and percent change from baseline over time after Study Drug administration, as appropriate.  
Vital sign , weight, and ECG measures will be summarized  by treatment group.  In addition, the 
number of patients who experience abnormalities in clinical laboratory  evaluations will be 
summarized by treatment group. 
10.5.3 Efficacy Analysis  
The 2 primary endpoints (mNIS +7 and Norfolk QOL- DN questionnaire total score ) will be 
analyzed using a ranking strategy with the mNIS +7 tested first and the Norfolk QOL- DN tested 
second.  The primary efficacy analyse s will be (1) the comparison of change from baseline to 
Week 66 in mNIS+7  between ISIS  420915 300 mg group and placebo group in the Full Analysis 
Set and (2) the comparison of change from baseline to Week 66 in Norfolk QOL- DN 
questionnaire total score between ISIS 420915 300 mg group and placebo group in the Full 
Analysis set .  Interpretation will be made in a stepwise approach, i.e. should the null hypothesis 
for the mNIS+7 be rejected, then the null hypothesis for the Norfolk QOL-DN questionnaire 
total score will be tested.  However, if the null hypothesis for the mNIS+7 is not rejected, testing 
for the Norfolk QOL- DN questionnaire total score will be conside red exploratory.  No 
adjustment will be made for multiple testing (both endpoints will b e tested at an alpha of 0.05). 
The data will be analyzed using a Mixed Effect s Model with Repeated Measures ( MMRM 
model) where the treatment group, time, 3 randomizatio n stratification  factors , and treatment by 
time interaction will be included in the model as fixed effects; patient will be a random effect .  
The baseline by time  interaction will be included if appropriate.  No imputation for missing data 
will be made.  The 2 assessments at each timepoint  (except Week 35 that includes only 
1 assessment)  will b e averaged at component level.  
For each primary endpoint, a cumulative distribution function plot will be used to show the 
distribution of change from baseline to Week 66 in individual patients by treatment group. 
The primary efficacy analyse s will take place after all patients have completed the treatment and  
EOT efficacy assessments and the database has been locked.  Evaluation of the model will be 
performed.  The details of model che cking and alternative analyses approach will be provided in 
the S AP that will be finalized prior to the final database lock . 
The following sensitivity analyses will be conducted for both of the primary efficacy endpoints, 
and details of the analysis are outlined in the SAP: 
• Comparison of change from baseline to Week 66 in mNIS+7 score and Norfolk QOL- DN 
questionnaire total score  between ISIS  420915 300 mg and placebo group in the Per-
Protocol Set 
• A variety of multiple imputation methods will be used to investigate the impact of different patterns of missing data 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
61  • Addition of pooled investigative site to the primary efficacy MMRM model, where 
pooled site will be specified in the SAP prior to unblinding.  The interaction between 
treatment and pooled site will be examined if model convergence permits 
• Responder analysis (for mNIS+7 only)  to examine if the improvement in response is 
consistent over a range of response threshold s.  If a patient  terminates treatment early due 
to AE or lack of ef ficacy or other types of treatment failure,  then the response of the 
patien t is considered as non -responder.  Other missing val ues are considered as censoring  
o For the set of response thresholds, the proportion of responders will be plotted against 
the resp onder threshold by treatment group 
Secondary efficacy analyses include:  
• Comparison of change from baseline to Week 66 in the Norfolk QOL- DN questionnaire 
symptoms domain score (Stage 1 patients) and Norfolk QOL-DN questionnaire physical functioning/large fiber neuropathy domain score (Stage 2 patients) between ISIS 420915 300 mg and placebo group in the Full Analysis Set 
• Comparison of change from baseline to Week 65 in mBMI  and BMI between  
ISIS 420915 300 mg and placebo group in the Full Analysis Set 
• Compar ison of change from baseline to Week 66 in the NIS , modified +7, and NIS+7 
between ISIS 420915 300 mg and placebo group in the Full Analysis Set.  Comparison of change from baseline to Week 66 in Norfolk QOL- DN domain  score s (symptom s domain 
for Stage 1 patients and physical functioning/large fiber neuropathy domain for Stage 2 patients) , NIS , modified +7 and NIS+7 , and change from baseline to Week 65 in mBMI 
and BMI between ISIS 420915 300 mg and placebo group in the Per-Protocol Set 
• Comparison of change from baseline to Week 65 in GLS by ECHO in the ECHO 
subgroup and in the CM- ECHO S et 
Tertiary analyses include:  
Comparisons of change from baseline to Week 65 in SF-36 questionnaire domain  scores, and 
change from baseline to Week 66 in individual components of NIS (cranial, muscle weakness, 
reflexes and sensory), modified +7 (hea rt rate to deep breathing, nerve conduction, heat-pain 
sensory and touch-pressure sensory testing) and +7 (vibration detection threshold and nerve conduction) , +7, and individual domain scores of Norfolk QOL- DN (physical functioning/ large 
fiber neuropathy, symptoms, activities of daily living, small fiber neuropathy and autonomic neuropathy) between ISIS  420915 300 mg and placebo group in both Full Ana lysis Set an d Per -
Protocol set .  The secondary and tertiary analyses  except GLS  will be  conducted in the same way 
as for the primary endpoint.  The analysis for  GLS by ECHO in the ECHO  subgroup and in the 
CM-ECHO Set will be specified in the ECHO SAP.  
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
62  10.5.4 Pharmacokinetic Analysis 
For all patients, pre-dose ISIS  420915 plasma concentrations will be summarized using 
descriptive statistics.  In addition, non -compartmental pharmacokinetic analysis of ISIS  420915 
concentrations will be carried out on each individual patient data set, and the plasma disposition 
half- life (t 1/2λz) associated with the apparent terminal elimination phase will be calculated, if 
appropriate, using available data (Day 449 and later), from the equation, t 1/2λz = 0.693/ λz, where 
λz is the  rate constant associated with the apparent terminal elimination phase. 
For patients in the PK subgroup only, non-compartmental pharmacokinetic analysis of ISIS 420915 will be carried out on each individual patient data set.  The maximum observed 
drug conc entration (C
max) and the time taken to reach C max (Tmax) will be obtained directly from 
the concentration -time data.  Following single dosing (Day 1), area under the plasma 
concentration -time curve from zero time (pre -dose) to 24 hours after the dose (AUC 0-24hr) will be 
calculated using the linear trapezoidal rule.  Following multiple dosing (Days 240 and 449), 
AUC 0-24hr and area under the plasma concentration -time curve during the time of each sampled 
dosing interval (tau,τ) at steady- state (AUC τ) will be calculated using the linear trapezoidal rule. 
Other pharmacokinetic parameters, as appropriate, may be determined or calculated at the discretion of the pharmacokinetic scientist. 
Plasma pharmacokinetic parameters will be summarized using descriptive statistics.  Additional 
details regarding the pharmacokinetic analysis will be described in the SAP. 
There is no statistical rationale for the selected s ample size of the PK subgroup.  The PK 
subgroup size of approximately 20 patients (to give approximately 10 evaluable patients in the 
treated group assuming a dropout rate of 25%) was selected based upon prior clinical PK 
experience with ISIS 420915 and other 2′ -MOE -modified ASOs, and expected low- to- moderate 
inter- and intra -patient variab ility in PK paramete r measures.  
10.5.5 Pharmacodynamic Analysis  
Pharmacodynamic analyses include comparisons of change from baseline in TTR and RBP4  
between ISIS  420915 300 mg and placebo group.  The data will be analyzed in the same way as 
for the primary endpoint and will b e assessed in both the Full Analysis and Per -protocol 
populations. 
10.5.6 Exploratory Analysis 
Exploratory analysis includes the comparisons of change from baseline in ECHO parameters 
except GLS  (ECHO subgroup and CM- ECHO Set ), NT-ProBNP,  PND score and NSC score to 
Week 65 (Week 66 for NSC) between ISIS 420915 300 mg and placebo group.  Details of the analysis will be provided in the SAP and ECHO SAP . 
11. INVESTIGATOR'S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, from an English version provided by the Sponsor. 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
63  Before a patien t’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patien t after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol- specific screening 
procedures or any Study Drug products are administered.  The patient must be given sufficient 
time to consider whether to participate in the study. 
The acquisition of informed consent and the  patien t’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patien t’s medical records and the informed 
consent form should be signed and personally dated by the patien t and by the person who 
conducted the informed consent discussion (not necessarily an I nvestigator).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations 
required by institutional policy, and a copy of the signed consent form should be provided to the 
patient . 
11.2 Ethical Conduct of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsin ki dated 
October 2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands of national drug and data protection laws and other applicable regulatory requirements will be strictly followed.  
11.3 Independe nt Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent form, other written patien t information, and 
any proposed advertising material must be submitted to the IEC/IRB for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received by the 
Sponsor before recruitment of patien ts into the study and shipment of Study Drug.  A copy of the 
written approval of any other items/materials that must be approved by the Study Cen ter or 
IEC/IRB  must also be received by the Sponsor before recruitment of patien ts into the study and 
shipment of Study Drug.  The Investigator’s Brochure must be submitted to the IEC/IRB for  
acknowledgement. 
The I nvestigator must submit to and, where nece ssary, obtain approval from the IEC/IRB for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IR B of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IEC/IR B of serious adve rse events 
occurring at the Study Center and other adverse event reports received from the Sponsor, in accordance with local procedures.  
The Investigator will be responsible for obtaining annual IE C/IRB approval/renewal throughout 
the duratio n of the study.  Copies of the I nvestigator’s reports , all IEC/IR B submissions and the 
IEC/IR B continuance of approval must be sent to the Sponsor. 
11.4 Patient  Confidentiality  
The I nvestigator must ensure that the patien t’s confidentiality is maintained.  On the case report 
forms or other documents submitted to the Sponsor, patien ts should be identified by patien t study 
number only.  Documents that are not for submission to the Sponsor (e.g., signed informed consent forms) should be kept in strict confidence by the I nvestigator.  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
64  In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the patien t’s original medical records for 
verification of study-related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any re cords and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patien t to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patien t. 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
12.1 Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor.  Agreement from the Investigator must be obtained for all protocol amendments and amendments to the informed consent document.  The regulatory authority and IEC/IRB  must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the patien ts or 
the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IEC/IRB  to the S ponsor. 
12.2 Study Termination  
The Sponsor  reserves the right to terminate the study, according to the terms of the study 
contract.  The Sponsor should notify the IEC/IRB  in writing of the trial’s completion or early 
termination . 
12.3 Study Documentation and Storage  
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor -approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the patient ’s case report 
form data are obtained.  These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, 
CRFs may not be used as source documents.  
The Investigator and S tudy Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8 of the ICH Guidelines (E6), suitable for inspection at any time by representatives from 
the Sponsor  and/or applicable r egulatory authorities.  Elements should include: 
• Patient  files containing completed case report forms, patient dosing diaries, informed 
consents, and supporting copies of source documentation 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copies 
of pre-study documentation and all correspondence to and from the IEC/IR B and the 
Sponsor 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
65  • If drug supplies are maintained at the Study Center, proof of receipt, Study Drug Product 
Accountability Record, Return of Study Drug Product for Destruction, Final Study D rug 
Product Reconciliation Statement, and all drug- related correspondence  
In addition, all original source documents supporting entries in the case report forms must be 
maintained and be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor  
and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify the Sponsor . 
12.4 Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that patient  confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the case report forms at regular intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  
The monitor should have access to patient medical records and other study -related records 
needed to verify the entries on the case report forms. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinic al Quality Assurance Department .  Inspection of 
Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study-related records will occur to evaluate the trial conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data received by the Sponsor.  During this review, patient data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center notifications will be sent to the 
Study Center for completion and return to Sponsor. 
The Principal Investigator will sign and date the indicated places on the case report form.  These 
signatures will indicate that the principal Invest igator inspected or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content. 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
66  12.5 Language 
Case report forms must be completed in English.  Generic names for concomitant medications 
should be recorded in English if possible, unless it is a combination drug, then record the t rade 
name in English. 
All written information and other material to be used by patien ts and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws.   Patient s will be treated and/or compensated for any study-
related illness/injury in accordance with the information provided in the Compensation for Injury 
section of the Informed Consent document. 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
67  13. REFERENCES  
Adams D, Samuel D, Goulon -Goeau C, et al. The cou rse and prognostic factors of familial amyloid polyneuropathy 
after liver transplantation. Brain 2000; 123: 1495 -1504.  
Adams D. Phase 2 Open -Label Extension Study of Patisiran – An Investigational RNAi Therapeutic for the 
Treatment of Familial Amyloidotic Polyneuropathy. 67th Annual Meeting of the American Academy of Neurology 
(AAN) being held April 18 – 25, 2015 in Washington, D.C. (http://www.alnylam.com/web/assets/PATISIRAN -
12MONTHOLE -AAN -FINAL_Capella.pdf) 
Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy. Neurology 2015; 85: 
1-8. 
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals. Chimia 1996; 50: 168 -176. 
Ando Y, Naka mura M, Araki S. Transthyretin -related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 
1057 -1062.  
Benson MD, Teague SD, Kovacs R, et al. Rate of progression of tranthyretin amyloidosis. Am J Cardiol 2011; 
108(2): 285 -289. 
Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical 
trial. JAMA 2013: 310(24): 2658- 26673.  
Biesalski HK, Frank J, Beck SC, et al. Biochemical but not clinical vitamin A deficiency results from mutations in 
the gene for retinol binding protein. Am  J Clin Nutr 1999; 69:  931-936. 
Bui BV, Armitage JA, Fletcher EL, et al. Retinal anatomy and function of the transthyretin null mouse. Exp Eye Res 
2001; 73: 651-659. 
Chi KN, Eisenhauer E, Fazli L, et al. A Phase I pharmacokinetic and pharmacodynamic study of Ogx- 011, a 
2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the 
National Cancer Institute 2005; 97: 1287 -1296.  
Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX -011): A second -generation antisense inhibitor of clusterin for the 
treatment of cancer. Expert Opin Investig Drugs 2008; 12: 1955- 1962.  
Coelho T, Ericzon B, Falk R, et al. A physician's guide to transthyretin amyloidosis. Amyloidosis Foundation 2008; 
1-16. 
Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a 
randomized, controlled trial. Neurology 2012; 79: 785- 792. 
Coutinho P, Martins da Silva A, Lopas Lima J. et al. Forty years of experience with type  1 amyloid neuropathy.  
Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, ed itors. Amyloid and Amyloidosis.  
Amsterdam, The Netherlands 1980.  
Crooke ST and Bennett CF. Progress in antisense oligonucleotide therapeutics. Annual Review  of Pharmacology 
and Toxicology 1996; 36: 107 -129. 
Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester diabetic neuropathy study: design, criteria for types of 
neuropathy, selection bias, and reproducibility of neuropathic test. Neurology 1991; 41: 799 -807. 
Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score 
in the Rochester diabetic neuropathy study cohort. Neurology 1997; 49: 229 -239. 
European Medicines Agency. Assessment report for Vynaqel.  
http://www.ema.europa.eu/docs/en_GB/document_library/  EPAR_ -_Public_assessment_report/human/002294/ 
WC500117838.pdf 
Episkopou V, Maeda S, Nishiguchi S, et al. Disruption of the transthyretin gene results in mice with depressed 
levels of pla sma retinol and thyr oid homone. Proc. Natl Acad. Sci. 1993; 90: 2375- 2379 . 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
68  Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. NEJM 1997; 337: 898 -909. 
Falk RH. Progressive deterioration in cardiac function in senile systemic amyloidosis detected by LV speckle strain 
imaging. VIIIth International Symposium on Familial Amyloidotic Polyneuropathy. Kumamoto, Japan: Nov 20- 22, 
2011 . 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2' -O-(2-
methoxyethyl) modified antisense olig onucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419–
1428.  
Henry SP, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation 
in mice. J Pharmacol Exp Ther 2000; 292: 468- 479. 
Henry SP, Kim T W, Kramer- Stickland K, et al. Toxicologic prope rties of 2′ -O-methoxyethyl chimeric antisense 
inhibitors in animals and man. In Crooke ST, editor, Antisense Drug Technology, Principles, Strategies and Applications. Boca Raton, FL, Taylor & Francis Group, 2n d Edition. 2008; 2: 327 -364. 
Herlenius G, Wilczek HE, Larsson M, et al; and Reporting Members of the Familial Amyloidotic Polyneuropathy 
World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation 
2004 ; 77: 64 -71. 
Inoue H, Hayase Y, Iwai S, et al. Sequence -dependent hydrolysis of RNA using modified oligonucleotide splints 
and RNase H. FEBS L etters 1987; 215: 327- 330. 
Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low -density lipoprotein 
cholesterol by short -term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 
1729 -1735.  
Kwoh TJ. An overview of the clinical safety experience of first and second generation antisense oligonucleotides. 
In: Crooke ST, editor. Antisense Drug Technology: Principles, Strategies and Applications, 2nd Edition. Boca Raton . FL. Taylor & Francis Group 2008; 365 -400. 
Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: 
Crooke ST, editor. Antisense Drug Technology: Principles, Strategies and Applications. 2nd Edition. Boca Raton, 
FL. Ta ylor and Francis Group 2008; 183- 215. 
McKa y RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression.  J Biol Chem 1999; 274: 1715 -1722.  
Monia BP, Lesni k EA, Gonzalez C, et al. Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as 
antisense i nhibitors of gene expression. J  Biol Chem 1993; 268: 14514-14522.  
Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloido tic polyneuropathy: impact on 
Swedish patients' survival. Liver Transplantation 2009; 15: 1229 -1235.  
Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N -terminal natriuretic 
peptide type B decrease simultaneous ly in association with improvement of survival in AL. Blood 2006; 107: 
3854 -3858 . 
Plante -Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid 
polyneuropathy (TTR -FAP). Neurology 2007; 69: 693- 698. 
Raal FJ,  Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL 
cholesterol concentrations in patients with homozygous familial hypercholesterolaemia : a randomized, double -blind, 
placebo -controlled trial. Lancet. 2010 M ar 20; 375(9719): 998- 1006.  
Santos R, Duell PB, East C, et al. Long -term safety and efficacy of mipomersen in patients with familial 
hypercholesterolemia not controlled by maximally tolerated lipid lowering therapy.  XVI International Symposium 
on Atheroscl erosis – ISA, March 25 -29, 2012; Sydney, Australia . 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
69  Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical 
investigations of antihemostatic medical products in non -surgical patients. J Thromb Haemost 2005; 3(4): 692- 694. 
Sekijima Y, Yoshida K, Tokuda T, et al. Familial transthyretin amyloidosis. Gene  Reviews 2009; [Internet], 
Pagon RA, et al. editors. Seattle, WA.  
Sewell KL, Geary RS, Baker BF, et al. Phase 1 trial of ISIS  104838, a 2′ -methoxyethyl modified antisense 
oligonucleotide targeting tumor necrosis factor -alpha. J Pharmacol Exp Ther 2002; 303: 1334- 1343.  
Stangou AJ and Hawkins PN. Liver transplantation in transthyretin -related familial amyloid polyneuropathy. Curr 
Opin Neurol 2004; 17: 615 -620. 
Vinik EJ, Vinik AI, Paulson JF, et al. Validation of Norfolk QOL -DN as a  measur e of QOL in patients with 
transthyretin familial amyloid polyneuropathy. Poster at the Biennial Meeting of the Peripheral Nerve Society, 
June 25-29, 2011; Potomac, Maryland. 
Waits RP, Yamada T, Uemichi T, et al. Low plasma concentrations of retinol -binding protein in individuals with 
mutations affecting position 84 of the transthyretin molecule. Clin Chem  1995; 41: 1288- 1291.  
Wei S, Episkopou V, Piantedosi R, et al. Studies on the metabolism of retinol and retinol -binding protein in 
transthyretin -deficient mice produced by homologous recombination. Journal of Biological Chemistry 1995; 270(2): 
866-870. 
Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway Factor XI by antisense 
oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 468 4-4692.  
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
70   
 
 
  
 
 
14. APPENDICES  
   
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
71   
 
 
  
 
 
Appendix A Schedule of Procedure s 
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
72  Appendix A Schedule of Procedures 
 
  EOT
Efficacy
W W W W W W W W W W W W W W W W W W W W W W W
3 5 8 10 13 15 18 20 23 26 29 32 38 41 44 47 50 53 56 59 62 65 66
D D D D D D D D D D D D D D D D D D D D D D D D D D D D
1 3 5 15 29 50 64 85 99 120 134 155 176 197 218 239 240 260 281 302 323 344 365 386 407 428 449 456
Visit Window (+/- Days) 0 0 0 2 2 2 2 2 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 7
Informed Consent X
Inclusion/Exclusion X
Medical History X
Height X
HIV, Hepatitis B & C X
Biopsy for Amyloid3X
TTR Genotyping3X
Study Drug Admin. X X X X X X X X X X X X X X X X X X X X X X X X X X
Physical Exam X X X X X X
Vital SignsA
(BP4, HR, RR, temp)
ECG (12-Lead, triplicate) X XCXAXAXA
Pregnancy Test5X XAX X X X X
Chemistry Panel (Fasting) AX X X X X X X X X X X X X X X X X X X X X
Serum Creatinine (Fasting) X X X X X X
Hematology AX X X X X X X X X X X X X X X X X X X X X X X X X X
Weekly Platelet Monitoring10
Urinalysis AX X X X X X X X X X X X X X X X X X X X
24 hour Urine X
Thyroid PanelAX X X X X X
Inflammatory PanelAX X X X X X X X X
PT, aPTT, INRAX X X X X X X
Complement (C3)AX
ImmunogenicityAX X X X X X
AE & Conmeds & 
Concomitant ProceduresX X X X X X X X X X X X X X X X X X X XX X X X X X X X X X X
Weekly Platelet MonitoringX X X X X X X XStudy Day S-42 to S-1
XStudy Week W -6 to -11W
1W
35ScreenBas eline 
Asse ss-
mentsTreatment (65 Wks)
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
73  Appendix A Schedule of Procedures Continued  
 
 EOT
Efficacy
W W W W W W W W W W W W W W W W W W W W W W W
3 5 8 10 13 15 18 20 23 26 29 32 38 41 44 47 50 53 56 59 62 65 66
D D D D D D D D D D D D D D D D D D D D D D D D D D D D
1 3 5 15 29 50 64 85 99 120 134 155 176 197 218 239 240 260 281 302 323 344 365 386 407 428 449 456
Visit Window (+/- Days) 0 0 0 2 2 2 2 2 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 7
NIS6X
mNIS+7 Assessment72X X 2X
Norfolk QOL-DN7X X X
SF-36 QuestionnaireAX X X
PND Score X X X
Body Weight (Fasting) X X X X X X
PD Panel (Fasting)AX X X X X X X X X X X X X X X
PK TroughAX X X X X X X X X X X X X X
Transthoracic ECHO8X X X
NT-proBNPAX X X X
Retinol (Fasting)AX X X X X X X
ERG Exam9X X
Ophthalmology Exam9X X X
C-SSRS XAX X X X
PK AUC/Trough Blood XBXAXAXAXAXAXAXAXAXAXFXAXAXAXAXF
ECG (12-Lead, triplicate) X XCXCXC
Complement (C5a, Bb) XCXAXAXAXAXCXC
PT, INR, aPTT XDXAXAXAXAXDXD
Inflammatory Panel XAXAXAXAXAXAXAXEXE
Hematology X XAXAXAXAXAXAXAXAXAXAXAXAXAXAXAXEXAXAXAXAXAXAXAXAXAXEAdditional Tests for PK Subgroup Only (n = 20)Study WeekW
-6 to -11W
1W
35
Study Day S-42 to S-1ScreenBas eline 
Asse ss-
mentsTreatment (65 Wks)
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
74  Appendix A Schedule of Procedures Continued  
 Post Treatment Evaluation Period  
  W W W W W W W W
67 69 71 74 77 80 83 91
D D D D D D D D
463 477 491 512 533 554 575 631
Visit Window (+/- Days) 7 7 7 7 7 7 7 7
Informed Consent
Inclusion/Exclusion
Medical History
Height
HIV, Hepatitis B & C
Biopsy for Amyloid3
TTR Genotyping3
Study Drug Admin.
Physical Exam X X
Vital SignsA
(BP4, HR, RR, temp)
ECG (12-Lead, triplicate) X X
Pregnancy Test5X X X
Chemistry Panel (Fasting) AX X X X
Serum Creatinine (Fasting) X X X X X
Hematology A X X X X X X X X X
Weekly Platelet 
Monitoring10
Urinalysis AX X
24 hour Urine
Thyroid PanelAX X
Inflammatory PanelAX X X
PT, aPTT, INRAX X
Complement (C3)A
ImmunogenicityAX X X
AE & Conmeds & 
Concomitant ProceduresX X X XWeekly Platelet MonitoringPost-Treatment Evaluation Period Early 
Term (6 Mo)2
X X X XStudy Week
Study Day
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
75  Appendix A Schedule of Procedures Continued  
 Post Treatment Evaluation Period  
 
Note:  If not specifically labeled, “X” means anytime.  Shaded columns represent visits with the option to be completed in clinic, by a home healthcare service, or by a local 
laboratory with prior Sponsor  approval.  
 W W W W W W W W
67 69 71 74 77 80 83 91
D D D D D D D D
463 477 491 512 533 554 575 631
Visit Window (+/- Days) 7 7 7 7 7 7 7 7
NIS6
mNIS+7 Assessment7X EOT
Norfolk QOL-DN7X EOT
SF-36 QuestionnaireAX X
PND Score X X
Body Weight (Fasting) X X X
PD Panel (Fasting)AX X X X
PK TroughAX X X X
Transthoracic ECHO8X
NT-proBNPAX X X
Retinol (Fasting)AX X X X
ERG Exam9X
Ophthalmology Exam9X
C-SSRS X X
PK AUC/Trough Blood X X X X
ECG (12-Lead, triplicate) X X
Complement (C5a, Bb) X X
PT, INR, aPTT X X
Inflammatory Panel X X X
Hematology XAXAX XAX XAXAX XPost-Treatment Evaluation Period Early 
Term
Study Week
Additional Tests for PK Subgroup Only (n = 20)(6 Mo)2
Study Day
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
76  Appendix A  Schedule of Procedures Continued  
1 A 6- week period is given to complete the screening/baseline assessments.  Ideally, the baseline assessments should be conducted after patient eligibility is 
determined.  
2 After completing the Week 66 efficacy assessments, patients will enter the post -treatment evaluation period.  However, eligible patients may elect to enroll in 
an OLE study pending study approval by the IRB/IEC and the appropriate regulatory authority. In this case, patients will not participate in the post -treatment 
evaluation period.  
3 For determination of patient eligibility only if appropriate documentation is not available. In this case the tests may be conducted up to ten weeks prior to 
Day 1.  For biopsy, location per local practice.  
4 Blood pressure should be taken after patient has been sitting for ≥  5 min.  
5 For females of child- bearing potential only, by serum βhCG except on Day 1 were urine hCG is tested pre-dose. 
6 At Screening for determination of eligibility only (+7 not needed).  For an individual patient, every effort should be made to use the same NIS evaluator 
throughout the study and the NIS evaluator must be insulated from the patient’s general study procedures and knowledge of the patient’s adverse events.  
7 The Norfolk QOL-DN questionnaire must be administered prior to any other study procedures. During the baseline and EOT efficacy assessment periods, the Norfolk QOL -DN questionnaire should be administered on the same day as the first mNIS+7 assessment.  The mNIS+7 assessment procedure includes the 
NIS, +7, NSC, and additional sensory and nerve conduction testing.  If an ERG or ophthalmology examination are to be conducted on a mNIS+7 assessment day, the mNIS+7 assessment must be conducted first.  
• Two (2) independent mNIS+7 assessments will be performed at Baseline on separate days.  Both assessments should be performed within 14 days prior 
to the first dose of Study Drug (Day  1).  In addition, every effort should be made to conduct the two assessments <  7 days apart.  
• mNIS+7 and Norfolk QOL-DN assessments at Week 35 (D239) must be conducted approximately >  24 hours from the previous weeks dose.  
• Two independent mNIS+7 assessments will be performed at Week 66 on separate days.  Both assessments must be performed within 14 days from the last dose of Study Drug.  The first mNIS+7 assessment must be conducted approximately >  24 hours from the last dose of Study Drug.  In addition, every 
effort should be made to conduct the two assessments <  7 days apart.  The EOT efficacy assessment should also be performed on patients that 
terminate treatment early, ideally within 14 days of the last dose of Study Drug.  
8 Transthoracic ECHO  
• The baseline, Week 65 and early term ECHOs are conducted on all patients.  
• The Week 41 ECHO is only conducted in patients participating in the ECHO subgroup and can be done at Week 47 if the patient elects to have a Home Healthcare visit at Week 41.  
• There is a window of ± 2 weeks for all ECHOs.  
9 ERG  and ophthalmology examinations  
• The Week 29 and Week 65 examinations have a window of ± 2 weeks. The baseline ERG and ophthalmology examinations may be done up to 1- week 
after Study Day 1 if needed for scheduling purposes (except for Ile84 patients that fall under exclusion criteria 3 and should have eye examinations 
performed to determine eligibility).  Week 65 ERG and ophthalmology examinations may be done at Week 59 if needed for scheduling purposes.  
• The early termination (Early term) ERG and ophthalmology examinations are only done if the patient discontinues treatment after ≥  9 mo of dosing.  
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
77  Appendix A  Schedule of Procedures Continued  
Legend  Continued  
10 Weekly platelet monitoring is required throughout the treatment period and for a minimum of 6 weeks after the last dose of Study Drug (this includes early 
termination patients as well as patients that complete the full 65 week treatment period).  For patients participating in the Post -Treatment Evaluation Period, 
frequency of testing after the Week 71 visit will be determined by the Study Medical Monitor in consultation with the Investigator.  For patients participating in the ISIS 420915-CS3 study, weekly monitoring should continue between the last dose of Study Drug in CS2 and first dose of Study Drug in CS3.  If this period 
extends beyond 6 weeks, the frequency will be determined by the Study Medical Monitor.  
The following visits to collect platelet values are required in addition to the visits shown in the table.  These visits do not have specified windows to allow 
flexibility of scheduling but with the intent that platelets are assessed each calendar week.  Visits may be completed in clinic, by home healthcare service, or 
by a local laboratory : 
Week 2, 4, 6, 7, 9, 11, 12, 14, 16, 17, 19, 21, 22, 24,  25, 27, 28, 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57, 58, 60, 61, 63, 64, 66, 
68, and 70  
 
Time (time is in reference to Study Drug administration) : 
A Pre-dose (during treatment period)  
B Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6,  8, 12, and 24-hour  
C Pre-dose, 3 -hour  
D Pre-dose, 3 and 12-hour  
E Pre-dose, 24-hour, 3-day and 7-day  
F Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24-hour, 3-day and 7 -day.  For both E and F: where applicable, the 7-day blood draw should be taken before the next 
 weekly dose is given.  The 12- hr blood draw is encouraged but optional.  
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
78   
 
 
  
 
 
Appendix B  List of L aboratory Analytes  
 
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
79  Appendix B  List of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better characterize the profile of ISIS  420915 or other similar 
oligonucleotides 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN  
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT 
• AST 
• Alkaline phosphatase  
• Creatine kinase 
• Estimated creatinine 
clearance ( CKD-EPI) 
• Total IgM  
• Total IgG  
 Screening Tests  
• Hepatitis B surface antigen  
• Hepatitis C antibody  
• HIV antibody  
• Serum βhCG  
• Urine hCG  
• FSH 
 
Coagulation  
• aPTT (sec) 
• PT (sec) 
• INR 
 
Complement1 
• C3 
• C5a 
• Bb 
 
PD Panel1 
• Transthyretin  
• Retinol binding 
protein 4 (RBP4)  
 
24 hour Urine1 
• Creatinine  
• Protein  
• Albumin  
 Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharm acokinetics2 
• ISIS 420915 levels in 
plasma  
 
Thyroid Panel 
• Thyroid stimulating hormone (TSH)  
• Free T4 (FT4)  Urinalysis1 
• Color  
• Appearance  
• Specific gravity  
• pH 
• Protein  
• Blood  
• Ketones  
• Urobilinogen  
• Glucose  
• Leukocyte 
esterase  
• Nitrate  
• Microscopic 
examination3 
• P/C and Alb/C  
ratio 
 
Inflammatory 
Panel1 
• hsCRP  
 
Others 
• Retinol  
• Retinyl Palmitate  
• NT-proBNP  
• Immunogenicity  
1 Other  biomarkers may be measured, as needed; at  the discretion of the Sponsor.  B ack-up samples will be 
collected and stored.  For transthyretin, back- up samples may be analyzed in more sensitive transthyretin assay s 
at the discretion of the Sponsor .  Back-up urine samples may be analyzed for additional renal biomarkers . 
2 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments, immunogenicity testing, or to assess other actions of 
ISIS 420915 with plasma constituents  
3 Will be performed on abnormal findings  (if the initial analysis is positive for protein, blood, nitrite, &/or leukocyte 
esterase)  unless otherwise specified (to include: casts, crystals, bacteria, epithelial cells, RBC, WBC, yeast)  
  
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
80   
 
 
  
 
 
Appendix C PK Sampling Schedule  
 
ISIS 420915 -CS2 CONFIDENTIAL  Amendment 9  
Protocol   13 May 2016  
 
81  Appendix C  PK Sampling Schedule  
PK Sampling Schedule ( All Patients  except PK S ubgroup) 
D1 
(Wk 1) D15 
(Wk3) D29 
(Wk 5) D50 
(Wk 8) D85 
(Wk 13)  D120 
(Wk 18)  D155 
(Wk 23)  D197 
(Wk 29)  D240 
(Wk 35)  D281 
(Wk 41)  D323 
(Wk 47)  D365 
(Wk 53)  D407 
(Wk 59)  D449 
(Wk 65) D491 
(Wk 71) D533 
(Wk 77)  D631 
(Wk 91)  
Blood: 
Predose Blood:  Predose Blood: Predose Blood: Predose Blood: Predose Blood: Predose Blood: Predose Blood: Predose Blood: 
Predose  Blood: Predose Blood: Predose Blood: Predose Blood: 
Predose  Blood: Predose Blood: Anytime  Blood: Anytime  Blood: Anytime  
 
Extensive PK Sampling Schedule – ( PK Subgroup Only)1 
D1 
(Wk 1) D3 
(Wk 1) D5 
(Wk 1)  D15 
(Wk 3) D29 
(Wk 5) D50 
(Wk 8)  D85 
(Wk 13)  D120 
(Wk 18)  D155 
(Wk 23)  D197 
(Wk 29)  D240 
(Wk 35)  D281 
(Wk 41)  D323 
(Wk 47)  D365 
(Wk 53)  D407 
(Wk 59)  D449 
(Wk 65)  D491 
(Wk 71)  D533 
(Wk 77) D631 
(Wk 91) 
Blood: 
Predose , 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12, 24 hours 
Post SC 
Injection Blood: 
Pre-
dose Blood: Pre-
dose Blood: Pre- 
Dose Blood: Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: 
Predose
0.5, 1, 1.5, 2, 3,
 
4, 6, 8, 12, 24 hours, 
3 days, 
7 days 
Post SC 
Injection  Blood: 
Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: Pre-
dose Blood: 
Predose
0.5, 1, 1.5, 2, 3,
 
4, 6, 8, 12, 24 hours, 
3 days, 
7 days 
Post SC 
Injection  Blood: 
Any-time Blood: 
Any-time Blood: 
Any-time  
1 The 12-hr time -point is  encouraged but  optional  